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CHAPTER I 
 
INTRODUCTION  
 
Obesity Epidemic 
Obesity has increased at an alarming rate and now qualifies as a worldwide health 
epidemic (1-5). Currently, obesity affects 35.7% of adults and 20% of children in the United 
States of America (USA) (4, 6-8) and is an emerging disease in developing countries (1, 9-11). 
Obesity places a large burden on worldwide health care systems and economies. Many diseases 
associated with obesity have a serious impact on health, including diabetes, hypertension and 
coronary heart disease (12-20). These contribute to an increased risk of early mortality from 
stroke and heart attack (21-23). Chronic conditions like diabetes and hypertension require 
extensive medical intervention to manage. The direct medical costs in the USA associated with 
treating an increasingly obese patient population are estimated to be over $160 billion per year 
(24, 25).Equally costly, but less well known, is the strain obesity places on our economy, costing 
an additional estimated $140 billion per year due to lost productivity  (26). In addition to these 
economic costs is the high toll that obesity takes on human life, contributing to an estimated 
365,000 to 400,000 deaths per year in the USA (12, 18, 20). 
 
Factors involved in obesity epidemic 
In simple terms, obesity results when there is an imbalance between energy (food) intake 
and energy expenditure. J.V. Neel proposed a role for the environment to explain the obesity 
epidemic and its associated metabolic diseases over 50 years ago, and theorized that famine 
during human evolution favored genes that promote fat storage, but possession of this genotype 
may lead to greater susceptibility to obesity, when food is abundant and obtained with little effort 
(27). Certainly Neel’s “thrifty genotype” hypothesis provides a plausible explanation for why 
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some individuals become obese in an obesogenic environment, as well as the high heritability of 
obesity observed in families. A number of loci with small effect sizes for body weight, diabetes 
and fat mass have been identified by genome wide association scans (28), but a genetic basis for 
obesity susceptibility remains elusive  
Environment factors, including a sedentary lifestyle and consumption of high calorie, 
energy rich foods have been implicated in the obesity epidemic (10, 29). Epidemiological data 
show a positive correlation between obesity, measured by body mass index within populations, 
and dietary fat intake (30). The mechanisms involved in diet-induced obesity (DIO) have been 
studied extensively in rodent models for over 20 years (31). These models have shown that 
dietary lipid consumption induces pathophysiological changes in systems controlling energy 
balance within the central nervous system (CNS) (32).  
 
Energy homeostasis 
Coinciding with this alarming increase in the prevalence of obesity has been an 
exponential increase in our understanding of the systems involved in the regulation of energy 
homeostasis (33). Evidence indicates that body weight and adiposity can be tightly regulated 
physiologically through the coordinated action of distributed neurons and brain circuits, which 
regulate feeding and energy expenditure in response to changes in circulating hormones (34) and 
nutrients (35). A number of different signals are generated from the ingestion of food, and the 
metabolism and storage of nutrients (36). These signals control both long term and short term 
energy balance by regulating the size and frequency of meals (short term) as well as controlling 
total food intake and energy expenditure (long term) (37). In the model illustrated in Figure 1, 
energy homeostasis is controlled by an endocrine feedback loop in which adiposity signals, such 
as insulin and leptin, are involved in the long term regulation of energy homeostasis.  
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Figure 1. Central nervous system control of energy homeostasis.  
 
Energy balance is regulated by adiposity signals, such as insulin and leptin, which 
circulate in proportion to fat mass and signal energy excess to the central nervous 
system (CNS). By activating their respective receptors on neuronal subsets found in 
the hypothalamus and elsewhere, these hormones increase catabolic while decreasing 
anabolic activity resulting in lower food intake and greater energy expenditure. Figure 
adapted from Schwartz et al. 2000. Nature 404, 661-671. 
 .  
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Adiposity signals 
Adiposity negative feedback signaling in the CNS is a key mechanism involved in the 
regulation of energy balance. Several criteria define an adiposity negative feedback signal; it must 
be secreted in proportion to fat mass, it should be capable of interacting with neurons and cell 
types of brain areas that regulate energy balance, a deficiency should result in an obesity 
syndrome and administration of an adiposity negative feedback signal should affect feeding 
and/or energy expenditure. 
 
Leptin 
Leptin is an adipocyte-derived hormone that is secreted in proportion to energy stored as 
fat in adipose tissue (38) (Figure 1). Leptin was discovered through positional cloning 
experiments by J. Friedman’s group in 1994 (39) as a result of efforts to identify a genetic defect 
causing the obesity syndrome in the obese (OB) mouse (40). Leptin enters the brain where it 
activates receptors expressed on specialized neurons in the hypothalamus that regulate food 
intake and energy expenditure (41). Reductions in leptin are sensed in the brain, and activate 
powerful adaptive responses that oppose excessive fat loss, suggesting these systems evolved to 
protect against starvation (42, 43). The conclusion that leptin acts as an important adiposity signal 
is supported by the profound phenotype that occurs in the absence of leptin signaling, in OB mice 
which have a mutation in the gene that encodes leptin. The phenotype of ob/ob mice, which 
includes profound hyperphagia and obesity (40) is normalized by leptin treatment (42, 44). The 
importance of leptin in feeding regulation is further evidenced by several reported cases of 
genetic leptin deficiency in humans resulting in extreme childhood obesity (45), which is also 
drastically improved with exogenous leptin therapy (46, 47). These examples demonstrate the 
importance of intact leptin signaling in the regulation of energy balance.  
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Insulin 
The pancreatic β-cell hormone insulin is a well-established adiposity signal that acts in 
the brain (48). Like leptin, basal circulating levels of insulin are proportional to body fat stores 
(49-51). Insulin enters the brain through a receptor mediated saturable transport process (52). 
Insulin also reduces feeding and increases energy expenditure (Figure 1) by activating receptors 
expressed on neurons involved in energy balance in the hypothalamus (48). 
Intracerebroventricular (ICV) administration of insulin into the hypothalamus reduces food intake 
(53-55). Conversely, disruption of insulin signaling in the CNS, through specific genetic deletion 
of the insulin receptor (IR), causes hyperphagia and leads to obesity in mice (56). 
 
Satiety signals  
Satiety signals regulate short term feeding responses involving the size and frequency of 
meals by inducing feelings of satiation and satiety (57). Various chemo and mechano-receptors 
along the digestive track generate signals that are sent to the brain through vagal and taste 
afferents or through the circulation and provide information about the size and macronutrient 
composition (glucose, protein/amino acids, fatty acids) of a meal (58). Cholecystokinin (CCK) is 
one of the primary satiety signals involved in feeding regulation (57). CCK is released from 
duodenal mucosal cells in response to ingested protein and fat (59). The CCK signal is then 
transmitted by afferent fibers of the vagus nerve to the nucleus tractus solitarius (NTS) in the 
brain stem (60), which has projections to the hypothalamus where information is integrated into a 
response that results in meal termination (satiation) or suppression of hunger after meal (satiety). 
A number of other postprandial satiety signals are released from the gastrointestinal tract (GI) and 
have been shown to play important roles in feeding and appetite including glucagon-like-peptide 
(GLP)-1, amylin and peptide YY (reviewed in (57)).Ghrelin is another peptide hormone that is 
released from the GI tract and stimulates hunger and promotes feeding (61). 
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Reward circuitry: Mesolimbic dopamine system 
Food reward promotes feeding and is a non-homoeostatic regulator of feeding and energy 
balance. Dietary fat and sugar intake engage the mesolimic dopamine reward system, involving 
neurons in the ventral tegmental area (VTA) leading to dopamine and mu opiod release in the 
nucleus accumbens (62, 63), a region associated with drug addiction (64). Food restriction 
enhances the effects of drug reward (65-67). The reinforcing aspects of dopamine release on food 
reward are modulated by peripheral hormones and adiposity signals. Ghrelin signaling in VTA 
neurons increases dopamine levels in the nucleus accumbens (68) and promotes feeding (69). 
Leptin can inhibit feeding by modulating the activity of VTA neurons (70). Insulin is an 
important determinant of dopamine reuptake through regulation of dopamine transporter (DAT) 
translocation between intracellular vesicles and the plasma membrane. Evidence suggests that 
obesity is associated with defects in pre- and post-synaptic dopamine signaling and release (71-
73) which may contribute to impaired feeding regulation in obesity (74). Obesity may also impair 
dopamine signaling through decreased expression of dopamine D2 receptors (72, 73, 75).  
 
Central nervous system 
The regulation of energy balance is complex and involves many brain regions and 
neurological systems (76). Of these, the hypothalamus serves as a key region involved in the 
regulation of energy balance (34). The arcuate nucleus is a region in the medialbasal 
hypothalamus that is located near the third cerebral ventricle and is in close contact with the 
median eminence, an area distinguished by an incomplete blood brain barrier (77). Therefore, 
neurons in the arcuate nucleus are positioned to sense changes in concentrations of circulating 
hormones and nutrients. Neuronal subsets found in the arcuate nucleus express receptors for 
insulin and leptin and are differentially regulated by these hormones (Figure 2) (Reviewed in 
(41)). These act as first order neurons that assimilate and integrate information about adipose 
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Figure 2. Hypothalamic neurons involved in energy balance regulation.  
 
Two populations of neurons in the arcuate nucleus are known by the neuropeptides that they 
co-express, the neuropeptide Y (NPY) and agouti related protein (AgRP) orexigenic neurons 
as well as the proopiomelanocortin (POMC) and cocaine and amphetamine related transcript 
(CART) anorexigenic neurons. These co-expressing neurons are differentially regulated by 
circulating adiposity signals and satiety signals and differentially activate second order 
neurons that control food intake and energy expenditure (image from G.S. Barsh and M.W. 
Schwartz 2002. Nature reviews. Genetics 3, 589-600. 
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stores (long term energy availability), and orchestrate hormonal and autonomic responses via 
differential regulation of downstream neurons in the hypothalamus and other brain regions (37).   
 
Anorexigenic POMC/CART neurons 
The anorexigenic proopiomelanocortin (POMC) and cocaine and amphetamine related 
transcript (CART) (78, 79) co-expressing neurons are found in the arcuate nucleus and are 
activated during states of energy excess (Figure 2). Through the release of CART and the POMC 
cleavage product, α-melanocyte stimulating hormone (α-MSH), these neuropeptides activate 
CART and melanocortin receptors (MC3R/MC4R) receptors, respectively,  expressed on second 
order target neurons to decrease food intake and increase energy expenditure (80). Genetic 
defects in multiple steps of melanocortin signaling result in obesity in rodents highlighting the 
importance of this system in energy balance (reviewed in (81)). A frameshift mutation in the gene 
encoding MC4R is responsible for the most common form of monogenetic obesity known to 
occur in humans (82)  
 
Orexigenic NPY/AgRP neurons 
The neuropeptide Y (NPY) and agouti related protein (AgRP) co-expressing neurons in 
the arcuate nucleus release orexigenic neuropeptides, NPY and AgRP that increase food intake 
and reduce energy expenditure (83, 84) (Figure 2). NPY is a neuropeptide that binds a variety of 
NPY receptor subtypes expressed on neurons throughout the brain (Y1-5) (85, 86). Infusion of 
NPY into the third ventricle induces obesity in rodents (86). NPY is increased in the absence of 
leptin and genetic deletion of NPY attenuates obesity in ob/ob mice (87). AgRP is an endogenous 
MC3R/MC4R antagonist and blocks α-MSH signaling (88). In states of positive energy balance, 
insulin and leptin levels are elevated and inhibit NPY/AgRP neuronal firing and reduce gene 
expression of these neuropeptides (84, 89) thereby reducing orexigenic tone.  
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Second order neurons 
NPY/AgRP and POMC/CART neurons project to many of the same second order 
neurons to regulate food intake and energy expenditure through differential modulation of these 
neuronal targets (37) (Figure 2). Neurons in the lateral hypothalamic area (LHA) express food 
regulatory neuropeptides, such as orexin, CART, neurotensin, α-MSH and histamine, and are 
involved in feeding regulation (90). Neurons in the paraventricular nucleus (PVN) regulate 
endocrine responses related to metabolism and stress via thyroid releasing hormone and 
corticotrophin releasing hormones (reviewed (90)). Activation of POMC neurons leads to 
increased energy expenditure via α-MSH, which activates receptors expressed on neurons in the 
brain stem to increase sympathetic outflow to brown fat, muscle, pancreas, and liver (91-94).  
 
Hypothalamic insulin and leptin signaling 
Leptin signaling 
The effects of leptin are mediated through the long form of the leptin receptor, LEPR-B 
expressed on POMC/CART and NPY/AgRP neurons in the arcuate nucleus. LEPR-B is a type I 
cytokine receptor and activates a janus activating kinase 2 (JAK2) and signal transducer and 
activator of transcription-3 (STAT3) signaling cascade (44) (Figure 3). Leptin binding to the 
extracellular domain of LEPR-B induces a conformational change that induces JAK2 mediated 
tyrosine phosphorylation at three distinctive sites, Tyr1138, Tyr985 and Tyr1077 of the 
intracellular domain of LEPR-B. Phosphorylated-Tyr1138 recruits STAT3, where it is 
phosphorylated (pSTAT3) by JAK2, causing its nuclear translocation and transcriptional 
activation (reviewed (95)). In the nucleus, STAT3 promotes the expression of POMC and other 
gene targets including suppressor of cytokine signaling-3 (SOCS3), a STAT3  
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Figure 3 Insulin and leptin signaling in hypothalamic neurons.  
Insulin binding to its receptors (IR) leads to receptor tyrosine auto-phosphorylation, which 
recruits insulin receptor substrate (IRS) to the IR, where it undergoes tyrosine phosphorylation 
leading to recruitment of the p85 regulatory subunit of phosphoinositide 3-kinase (PI3K) and 
activation of and release of the catalytic subunit (p110) which phosphorylates membrane bound 
phosphatidylinositol (4,5) bisphosphate (PIP2) leading to the formation of phosphatidylinositol 
(3,4,5) trisphosphate (PIP3). Phosphatase and tensin homolog (PTEN) reverses the effects of 
PI3K, converting PIP3 to PIP2. PIP3 recruits protein kinase B/Akt to the membrane, where it is 
phosphorylated at two residues, by phosphoinositide dependent kinase 1 (PDK1) and 
mammalian target of rapamycin kinase complex (mTORC2) leading to its nuclear 
translocation. In the nucleus, Akt phosphorylates and promotes nuclear exclusion and 
inhibition of forkhead box protein O1 (FOXO1), resulting in regulation of neuropeptide gene 
expression. FOXO1 has differential effects in POMC and NPY/AgRP neurons. In POMC 
neurons, FOXO1 inhibits POMC expression. In these neurons, insulin signaling through PI3K 
promotes POMC expression via Akt mediated nuclear exclusion of FOXO1, which de-
represses the POMC promoter. FOXO1 promotes AgRP expression in NPY/AgRP neurons. In 
these neurons, insulin signaling reduces AgRP expression by excluding FOXO1 from the 
nucleus. Leptin binding to the long form of the leptin receptor, LEPR-B, recruits and activates 
Janus kinase 2 (JAK2) that phosphorylates LEPR-B, creating a binding site for transducer and 
activator of transcription-3 (STAT3), where it is phosphorylated and activated by JAK2. 
pSTAT3 monomers form dimers and translocate to the nucleus where they act as transcription 
factors to promote expression of POMC and suppressor of cytokine signaling-3 (Socs3), a 
STAT3 induced negative feedback regulator of LEPR-B activation in POMC neurons. Leptin 
signaling may also activate PI3K via JAK2 mediated phosphorylation and activation of IRS, 
resulting in decreased AgRP expression in NPY/AgRP neurons via FOXO1 inhibition. 
Ultimately, insulin dis-inhibits and leptin activates POMC expression while insulin deactivates 
and leptin inhibits AgRP expression. Figure adapted from Niswender and Schwartz. 2003. 
Frontiers in neuroendocrinology 24, 1-10. 
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induced negative feedback regulator of LEPR-B activation (96-98). Leptin signaling causes 
depolarization of POMC neurons (99) leading to neuropeptide release into the synaptic cleft near 
the axons of second order neurons, where CART and the POMC gene products αMSH activate 
their respective receptors ultimately reducing food intake and increasing energy expenditure. 
Leptin signaling has an opposite effect, hyperpolarizing anorexogenic NPY/AgRP neurons (78). 
The effects of leptin on POMC/CART neuron firing and gene expression are potentiated by 
insulin, which differentially regulates gene expression in POMC/CART and NPY/AgRP neuronal 
subtypes (Reviewed in (100)).  
 
Insulin signaling 
Insulin binding to insulin receptors (IR) expressed on POMC/CART and NPY/AgRP 
neurons causes IR to undergo auto-phosphorylation at key tyrosine residues on the intracellular 
domain, which serve as recognition and docking sites to recruit cytoplasmic insulin receptor 
substrate proteins (IRSs) (Figure 3) (reviewed in (101). IRSs are phosphorylated on tyrosine 
resides to facilitate recruitment through an interaction with the p85 regulatory subunit of 
phosphoinositide 3-kinase (PI3K), a key mediator in arcuate neurons of the insulin-induced 
inhibition of feeding (53). The catalytic subunit of PI3K, p110, phosphorylates membrane bound 
phosphatidylinositol (4,5) bisphosphate (PIP2) leading to the formation of phosphatidylinositol 
(3,4,5) trisphosphate (PIP3), which recruits protein kinase B (Akt) to the membrane, where it is 
phosphorylated. Akt phosphorylation by phosphoinositide dependent kinase 1 (PDK1) at 
threonine 308 (102), and at serine 473 by the mammalian target of rapamycin kinase complex 
(mTORC2), induces nuclear translocation where it phosphorylates and promotes exclusion of 
transcription factor forkhead box protein O1 (FOXO1) (103) from the nucleus. In the un-
phosphorylated state, FOXO1 binds to DNA and promotes AgRP expression in NPY/AgRP 
neurons and inhibits POMC expression in POMC/CART neurons (104). Therefore, insulin 
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reduces feeding, in part, by inhibiting AgRP expression and de-repressing POMC gene 
expression, via insulin induced phosphorylation and nuclear exclusion of FOXO1 (105). 
 
Inhibition of adiposity negative feedback signaling  
Negative regulation of insulin and leptin signaling occurs through several processes. 
SOCS3, which is upregulated by leptin signaling binds phosphorylated Tyr985 of LEPR-B and 
acts as a negative feedback regulator of STAT3 activation (96). SOCS3 is a negative regulator of 
insulin signaling, through ubiquitin mediated degradation of IRS1 and IRS2 (106). Consequently, 
chronic elevations in leptin can contribute to insulin and leptin resistance (98, 99). Phosphatase 
and tensin homolog (PTEN) reverses the effects of PI3K, converting PIP3 to PIP2 ultimately 
reducing the downstream effects of insulin and leptin signaling through this pathway (107) 
(Figure 3). A variety of protein tyrosine phosphatases (PTPs), enzymes that remove phosphate 
groups from phosphorylated tyrosine residues on proteins (108), can also act to reverse the effects 
of kinases involved in insulin and leptin signal transduction in hypothalamic neurons (109-112). 
Therefore, a balance between activation and deactivation of insulin and leptin signaling exists that 
allows for fine tuning and modulation of signal initiation, transduction and finally, squelching or 
conclusion of signal transduction. This allows for both acute regulation of neuronal activity, 
through effects on neuron firing, and chronic effects by modulating activity of the signaling 
molecules that regulate gene transcription.  
 
Integrated regulation of energy balance 
Reactive oxygen species 
Nutrients, such as glucose and fatty acids, and their intermediate metabolites can act as 
signaling molecules to modulate short term, metabolic responses in multiple tissues, including the 
brain. Circulating free fatty acids (FFA) increase during prolonged fasting due to lower 
circulating insulin levels and increased lipolysis. FFAs are oxidized through mitochondrial β-
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oxidation, which promotes production of reactive oxygen species (ROS) that are inherent 
byproducts of aerobic metabolism (113). At low concentrations, ROS can regulate insulin 
signaling through modulation of phosphatase activity (114, 115). Acutely, ROS serve as 
important nutrient signals and second messengers in hypothalamic neurons, where increased ROS 
simultaneously represses NPY while promoting POMC gene expression (116-118). Uncoupling 
protein 2 (UCP2) is a mitochondrial leak channel protein involved in hydrogen ion uncoupling 
across the mitochondria inner membrane. The regulatory effects of ROS to repress orexigenic 
neuronal activation and NPY neuropeptide expression are abrogated by mitochondrial uncoupling 
and reduction in ROS levels by UCP2 (116) through alterations in ATP production and neuronal 
firing. 
 
Obesity: Impaired energy homeostasis 
Caloric density of dietary fat  
Dietary fat intake has been implicated in the obesity epidemic (30, 31, 119). Several 
possible explanations have been offered. The increased caloric density of dietary fat is thought to 
contribute to elevated weight gain (120). Laboratory rodents rapidly develop obesity when fed 
experimental high-fat (HF) diets that contain 45-60% of total calories derived from fat instead of 
a chow diet (31, 121, 122). HF food, gram for gram, is more calorically dense than chow, having 
9 kilocalories (kcal) or 40% more kcal per gram than carbohydrates and protein which have 4 
kcal per gram. Caloric intake tends to be elevated in ad libitum HF diet feeding paradigms,  thus, 
inclusion of a pair-fed group, given access or restricted amounts of HF diet can help differentiate 
between the contributions of elevated caloric intake to DIO (123). A number of studies have 
reported detrimental metabolic effects of dietary fat that were independent of increases in total 
body weight, adiposity (124-128), and insulin resistance (129, 130). Therefore, while caloric 
intake is an important determinate of weight gain, dietary fat, among macronutrients, possesses 
unique obesogenic properties. 
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Hypothalamic insulin and leptin resistance  
Consumption of a HF diet is associated with central insulin and leptin resistance such that 
elevations in insulin and leptin no longer reduce food intake or increase energy expenditure 
resulting in expansion of adipose tissue and obesity (109, 131, 132). In animals with normal 
levels of adiposity, leptin, either peripherally or directly into the third ventricle, leads to a modest 
but significant decrease in 24 hour food intake. DIO attenuates the effects of leptin action on 
feeding (112, 133, 134). Behavioral leptin resistance in DIO animals is accompanied by cellular 
leptin resistance, measured by reduced activation of downstream signaling targets of leptin 
receptor signaling, such as reduced levels of phosphorylated STAT3 and JAK2 (132, 135, 136). 
Elevated levels of SOCS3 have been associated with obesity and resistance to leptin. SOCS3 is a 
known negative regulator of leptin signaling and may also promote insulin resistance (98, 99).  
Intracerebroventricular cannulation (ICV) is used to accurately assess behavioral and 
cellular insulin sensitivity in the CNS, due to the effects of exogenous peripheral insulin on 
glycemia. The effects of central insulin on feeding are attenuated or absent in DIO rodents (105, 
137, 138). DIO rodents also exhibit cellular hypothalamic insulin resistance after ICV insulin 
treatment; with reduced phosphorylation of IR, IRS, PI3K, Akt, and increased nuclear 
localization of FOXO1 (133, 137).  
 
Reduced energy expenditure 
In addition to excess food intake, obesity may result from a reduction in energy 
expenditure (139). Energy expenditure is defined as the sum of resting energy expenditure plus 
the energy expended from the thermic effect of food and physical activity. Resting energy 
expenditure encompasses the energy utilized to support basic cellular and physiological processes 
including circulation, respiration thermoregulation, growth and reproduction. The majority of an 
organism’s energy (~70%) is expended through these processes. When food is consumed, energy 
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is required for digestion, absorption and transport of nutrients, collectively termed the thermic 
effect of food which can account for 5-10% of total energy expenditure (140). Voluntary physical 
activity accounts for a small amount of all energy expenditure, although there is a large inter-
individual range that is dependent upon levels of exercise. Reduced energy expenditure is a 
feature of several genetic mouse models of obesity, including ob/ob (141) and MC4R knockout 
mice (142), which are characterized by reduced oxygen consumption, an indirect measure of fuel 
utilization and metabolic rate. 
Energy expenditure can be assessed by indirect calorimetry in which measurements of 
oxygen consumed (VO2) and carbon dioxide produced (VCO2) are measured and used to 
determine to the respiratory exchange ratio (RER). RER is then used to determine the respiratory 
quotient (RQ) (VCO2/VO2), the value of which indicates the type of fuel being oxidized. Pure 
carbohydrate oxidation yields an RQ value of ~1.0 while the expected RQ for pure fat oxidation 
is ~0.7. Typically, mixed meals, composed of fat and carbohydrate yield an RQ value that is 
intermediate between 0.7-1.0. Heat production (kcal/hr) can be determined from RER and VO2 
and indicates the total energy expenditure of an organism in calories. While energy expenditure is 
an important determinant of energy homeostasis, fat mass can accumulate in the absence of large 
changes in body weight due to reciprocal changes in lean mass.  
 
Fuel Partitioning 
Energy expenditure in genetic and DIO rodent models of obesity can be difficult to 
interpret due to drastic differences in body weight and/or body composition (143). When food 
intake and energy expenditure are not altered, higher adiposity can also be due to fuel partitioning 
and preferential storage of energy in adipose tissue as fat. Fuel partitioning can occur through 
several mechanisms that include alterations in adipose and lean mass metabolism and function. In 
adipose tissue, fat mass can accumulate due to differences in the rate of uptake of fatty acids from 
circulating triglycerides in lipoproteins, increased rates of lipogenesis and storage of newly 
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synthesized fatty acids in triglycerides or decreased lipolysis whereby fat is retained in adipose 
tissue due to decreased release of stored fatty acids from triglycerides. The phenotype of mice 
with global genetic deletion of MC3R is an example of a fuel partitioning phenotype. These 
animals have similar food intake and energy expenditure but exhibit increased adiposity and 
reduced lean mass with higher RQ which  suggests preferential glucose oxidation that promotes 
fat storage (144, 145). Fuel partitioning can also result from differences in the rates of protein 
synthesis and/or breakdown in lean tissue, which primarily occurs in skeletal muscle through 
myogenesis and proteolysis, respectively (146, 147). Skeletal muscle is a main site for fatty acid 
oxidation and glucose disposal; therefore reduced lean mass will have extensive metabolic 
implications related to glucose homeostasis and disposal as well as metabolic rate. Collectively, 
differences in fuel partitioning can lead to differences in body composition in the context of 
similar food intake and energy expenditure.  
 
Mechanisms involved in diet-induced obesity 
High-fat diet and hypothalamic inflammation  
Dietary fat intake is associated with systemic and cellular low-grade inflammation, which 
may serve as a key step in the development of insulin resistance in peripheral tissues (148-150). 
Increasing evidence suggests that after consuming a diet rich in saturated fat, circulating  
saturated fatty acids (SFAs) are elevated, which contribute to hypothalamic insulin and leptin 
resistance by activating inflammatory signaling pathways that inhibit insulin and leptin signaling 
in the CNS (reviewed (151)). Manipulations that reduce inflammatory signaling in the 
hypothalamus can prevent obesity and improve glucose metabolism (152). Direct infusion of a 
proinflammatory cytokine, IL-4, into the hypothalamus to activate inflammatory signaling, 
increases weight gain during HF feeding (153). Collectively, the evidence supports a causal 
relationship between hypothalamic inflammation, CNS hormone resistance and DIO.   
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Figure 4. Upstream mediators of NF-κB activation. 
 
 During HF feeding, cells are flooded with FFA from plasma activate inflammatory 
pathways including NF-κB. NF-κB is normally retained in the cytoplasm by IκBα. ER 
stress, toll-like receptor 4 (TLR4) activation by SFAs, and ROS production activate IKKβ, 
which phosphorylates and promotes the degradation of cytoplasmic IκBα resulting in 
nuclear translocation of NF-κB (p50/p65) and transcriptional activation of proinflammatory 
NF-κB cytokine target genes. IKK can also contribute to insulin resistance through 
inhibitory serine phosphorylation of the insulin receptor substrate molecules and inhibition 
of insulin receptor (IR) initiated signal transduction.  
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Inflammation: nuclear factor-kappa B 
DIO is commonly associated with activation of an inflammatory pathway involving the 
transcription factor, nuclear factor-kappa B (NF-κB), its regulatory protein, inhibitor of NF-κB 
alpha (IκBα), and the upstream kinase, IκBα kinase beta (IKKß) (133, 152). NF-κB has been 
associated with hypothalamic inflammation in response to toll-like receptor 4 (TLR4) activation 
by saturated fatty acids (SFAs) (154, 155), endoplasmic reticulum (ER) stress (152), and long-
chain fatty acyl CoA accumulation (133) (Figure 4). NF-κB signaling involves activation of 
IKKβ, which phosphorylates and promotes the degradation of cytoplasmic IκBα, resulting in NF-
κB release and transcriptional activation of numerous NF-κB target genes, such as 
proinflammatory cytokines interleukin-6 (IL-6), tumor necrosis factor alpha (TNFα) and 
interleukin-1beta (IL-1β) (156-159). These cytokines, produced locally within cells, can act in an 
autocrine manner to activate signal transduction cascades that contribute to oxidative stress and 
inflammatory signaling, which would further promote insulin resistance (149). IKKβ-NF-κB 
activation could also contribute to insulin resistance through IKKβ mediated serine 
phosphorylation and degradation of IRS molecules (160).  
 
Mitochondrial oxidative stress 
Mitochondrial oxidative stress is linked to inflammation and insulin resistance in 
numerous peripheral tissues (161-163) and is a common feature of neurodegenerative disease 
(164-167). Nutrient excess and increased flux through the mitochondrial respiratory chain 
increases the mitochondrial membrane potential, a situation that promotes superoxide anion 
production (O2˙ˉ) through reverse electron transport at complex I and III of the electron transport 
chain (113) (Figure 4). ROS accumulation due to chronic oxidative stress can overwhelm the 
cellular antioxidant defenses resulting in oxidative damage to DNA, proteins and lipids (168-
170). ROS also activate a variety of redox sensitive inflammatory kinases, including IKKβ, which 
contribute to insulin resistance through inhibitory serine phosphorylation of IRS signaling 
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molecules and increased cytokine expression (171). Genetic deletion of antioxidant genes leads to 
increased inflammation and insulin resistance, while treatment with antioxidants or 
overexpression of antioxidant genes prevents oxidative stress, inflammation, insulin resistance 
and apoptosis (reviewed in (172)). Biomarkers of oxidative stress correlate with dietary saturated 
fat intake in diabetic humans (173) and  evidence implicates mitochondrial dysfunction and 
oxidative stress in the pathogenesis of insulin resistance (162, 163, 174-178). However, the role 
oxidative stress might play within the hypothalamus during DIO is not known.  
 
ER stress 
The ER is the site of protein translation and folding, and defects in ER function are 
highly associated with obesity and insulin resistance (179). The higher demand on the ER to 
synthesize more proteins to respond to increased metabolic demands during overfeeding increases 
unfolded proteins in the ER inner membrane (180). These are sensed by ER stress sensors and 
unfolded protein response (UPR) transducers that halt protein translation until the defective 
proteins are cleared by ER chaperones (181). DIO models are associated with hypothalamic 
activation of the ER stress sensor protein kinase RNA-like endoplasmic reticulum kinase (PERK) 
and activation of this ER stress response modulator in the hypothalamus by overnutrition or 
TNFα (182) also activates the IKKβ-NF-κB pathway (152).  
 
Protective effects of monounsaturated fatty acids 
Dietary fat is consumed predominantly as triglycerides, composed of a glycerol backbone 
and three fatty acid chains. Fatty acids have distinctive structures, vary by chain length and 
saturation as well as position of unsaturated bonds. Epidemiological evidence suggests diets rich 
in monounsaturated fatty acids (MUFAs) have beneficial effects including improved insulin 
sensitivity, weight loss and reduced cardiovascular disease risk.(183). In human trials, 
monounsaturated dietary fat is less obesogenic than saturated fat (184-186), and improves insulin 
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sensitivity in obese and diabetic populations (187-192). The health benefits are independent of 
caloric intake (189, 193). The insulin sensitizing effects of dietary MUFA along with 
polyunsaturated fatty acids (PUFAs) are hypothesized to be due to the ability to interact with 
several different cellular “fatty acid sensors” (194) that reduce inflammation and/or attenuate 
lipid accumulation (194, 195). 
 
Peroxisome proliferator-activated receptors 
Discovery 
The peroxisome proliferator-activated receptor (PPAR) family of nuclear receptors, are 
lipid ligand activated transcription factors belonging to the nuclear hormone receptor super family 
(196, 197). PPARs were discovered as a result of efforts to identify the molecular mediator of 
fibrates, a class of amphipathic carboxylic acids used in the treatment of hyperlipidemic and 
metabolic disorders since 1967 (reviewed in (198)). First discovered in the 1952 (199, 200), 
fibrates were termed peroxisome proliferators after early studies showed they increased the 
number and size of peroxisomes in livers of rodents (201), and were later found to act by 
increasing the expression of genes involved in peroxisomal fatty acid β-oxidation (202). Attempts 
to synthesize more potent fibrate molecules in the early 1980’s resulted in the discovery of 
thiazolidinediones (TZDs), a class of related compounds that potently reduced hyperglycemia, 
hyperinsulinemia and hypertriglyceridemia in rodents (203-205). 
In 1990, Issemann and Green reported the discovery of a novel member of the nuclear 
hormone receptor super-family (197) that formed heterodimers with retinoid X receptor (RXR) 
and mediated the effects of fibrates and fatty acids on peroxisome proliferation and hepatic gene 
expression (206). In 1992, three related isoforms were identified in Xenopus, PPARα, PPARγ and 
PPARβ (later shown to be the same protein as PPARδ) (196). The PPARα isoform was confirmed 
as the molecular target of fibrates when genetic deletion ameliorated the effects of clofibrate and 
a related compound, Wy-14,643 in mice (207). PPARγ was shown to be the predominant isoform 
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in adipose (208) and was identified as the molecular target of TZD action the following year 
(209). The insulin sensitizing effects of TZDs were attributed to their ability to promote 
adipogenesis (210), thus reducing ectopic lipid accumulation and lipotoxicity in peripheral tissues 
such as liver and muscle (reviewed in (211)). PPARδ exhibited low affinity for fibrates (212) and 
research into its function and target genes lagged behind the other isoforms prior to the 
introduction of a chemical agonist in 2000 and two potent, selective agonists in 2003 (213, 214).   
 
 
Figure 5. Peroxisome proliferator-activated receptors. 
 
Circulating FFAs enter the cell and are transported to the nucleus by fatty acid binding 
protein (FABP). Once in the nucleus, FFAs are sensed by the peroxisome proliferator-
activated receptors (PPARs) family of nuclear receptors. When bound to fatty acid ligands, 
these “fatty acid sensors” dimerize with their obligate heterodimer partner retinoid X receptor 
(RXR) and bind the promoter of target genes containing the consensus PPAR response 
element (PPRE) sequence, leading to transcriptional regulation of target genes. 
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PPAR biology 
PPAR expression and function 
Collectively, PPARs are thought to be activated by dietary and endogenous fatty acids 
and regulate the expression of a diverse collection of target genes involved in fatty acid 
metabolism, mitochondrial function and inflammation (Figure 5). PPARα and PPARγ are 
expressed in a tissue specific manner, which reflect their biological functions as regulators of 
hepatic and adipose lipid metabolism, respectively (215, 216). PPARα is highly expressed in 
liver, where it regulates genes involved in fatty acid oxidation and lipoprotein metabolism (217-
219), and is involved in the adaptive response to fasting (220) (Figure 6). PPARγ is a master 
regulator of adipogenesis and adipose tissue function, and controls genes involved in fatty acid 
uptake and triglyceride storage (208, 211, 221) (Figure 6).  
PPARδ is ubiquitously expressed (212, 216) with the highest protein levels found in 
intestinal epithelium, liver, and keratinocytes (222) where it is involved in epithelial 
development, regulating lipid metabolism, and wound healing, respectively (223-226) . In 
skeletal muscle, PPARδ promotes the formation of oxidative, slow twitch fibers and is a key 
regulator of genes involved in fatty acid oxidation, mitochondrial biogenesis, electron transport 
and uncoupling (223, 227-231) (Figure 6). PPARδ is a critical regulator of lipid metabolism and 
mitochondrial function in cardiomyocytes (232-234) and has similar effects on mitochondrial 
function and lipid metabolism in less oxidative cells, such as adipocytes (235) and pancreatic β-
cells (236-238). Thus PPARδ is positioned to be an important determinant of cellular and tissue 
lipid homeostasis, energy utilization and inflammation.  
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Roles of PPAR isoforms in central energy homeostasis regulation 
All three PPAR isoforms are expressed to different degrees in  adult CNS (239). PPARα 
and PPARγ are expressed transiently during CNS development, while PPARδ is expressed at 
high levels in embryonic and adult CNS (215). Very little is known regarding the role of centrally 
expressed PPAR isoforms in CNS lipid metabolism and energy balance regulation. PPARγ is 
present in the medial basal hypothalamus, where it is co-expressed with NPY and POMC (117, 
240). Deletion of a floxed allele of PPARγ in neurons using Cre recombinase under the control of 
the Nex, a neuronal basic helix loop protein, promoter offers some protection against DIO (241). 
 
Figure 6. PPAR expression and function 
 
Tissue expression and biological roles of PPAR isoforms are illustrated. In liver, PPARα 
is involved in the adaptive response to fasting. PPARγ is a master regulator of 
adipogenesis and adipose tissue function. PPARδ is ubiquitously expressed and promotes 
fatty acid utilization as well as anti-inflammatory and antioxidant defense. All three 
isoforms are expressed in the CNS, where they are involved in neuroprotection. 
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Direct ICV administration of a chemical inhibitor of PPARγ recapitulated the effects of neuronal 
deletion on body weight and also reduced food intake in rats (242). In line with this, ICV 
administration of a chemical agonist increased weight gain (242), raising the possibility that HF 
diet consumption pathologically activates neuronal PPARγ facilitating obesity. PPARα is 
expressed at extremely low levels in the CNS (215, 239); however, there is evidence that it 
regulates several of its canonical target genes involved in fatty acid oxidation as well as 
hypothalamic pituitary axis (HPA) axis function within the pituitary and hypothalamus in 
response to fasting (243-246). Activation of both PPARα and PPARγ in the CNS has also been 
shown to promote peripheral glucose utilization (241, 247). Although limited, this evidence 
suggests a critical role in the CNS for the PPAR family of receptors in regulating energy balance 
and peripheral glucose disposal as well as neuronal lipid metabolism. 
 
Role of PPARδ in the central nervous system 
PPARδ is the most prevalent PPAR isoform in the CNS and is expressed abundantly in 
neurons throughout the brain  as well as some glial cells (239, 248). PPARδ expression is 
particularly enriched in oligodendrocytes of corpus collosum, and agonists of PPARδ promote 
oligodendrocyte differentiation and myelination in vitro (249-251). Higher levels of expression 
are found within neurons in the hippocampus, cortex and striatum, with the highest expression in 
the thalamus and hypothalamus (248, 252), where in situ hybridization and 
immunohistochemistry studies have shown it to be localized in neurons, cytosol and nucleus, with 
little expression in non-neuronal cells (239, 248).  
Genetic deletion of the ligand binding domain (LBD) of PPARδ, a region of the protein 
critical for transcriptional activation (253) leads to reduced brain size and myelination defects in 
corpus collosum of male mice (254), and altered CNS phospholipid composition in female mice 
(but not male) (255), providing some support for a role for PPARδ in CNS lipid metabolism and 
myelin formation. Despite the fact that this potent transcriptional regulator is highly expressed in 
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the CNS, little is known of the transcriptional targets regulated by PPARδ in the brain. More 
work is needed to understand the role of PPARδ, the most highly expressed isoform, in the brain. 
 
Neuroprotective effects of PPARδ 
Selective chemical modulators of PPARα and PPARγ, in particular, have potent anti-
inflammatory and neuroprotective effects (256, 257). The first evidence that PPARδ played an 
important protective role in the CNS came when PPARδ LBD mutant mice showed increased 
suceptability to ischemic injury, larger infarct size (258) and increased oxidative stress, the latter 
was accompanied by reduced expression of UCP2 (259). Studies conducted with highly selective 
PPARδ agonists revealed them to possess extensive neuroprotective qualities. Agonists of PPARδ 
attenuate brain inflammation, reduce demyelination in vitro (260) and reduce brain injury, in 
rodent models of neurodegenerative and neuroinflammatory diseases (261-263).  
 
Molecular biology of PPARδ 
Structure 
The mouse PPARδ gene was cloned in 1994 (212), but had been first reported in 1992 as 
PPARβ in Xenopus (196) and as NUC1 in human cells (264). The mouse PPARδ gene is 
contained in a 68,716 base pair (bp) region of DNA on chromosome 17 (Gene ID: 19015) 
containing 8 exons and encodes a 3,218 nucleotide (nt) mRNA transcript (NM_011145) that is 
translated to a 440 amino acid (aa) protein with a molecular weight of 49,584 kilodaltons (kD) 
(NP_035275). PPAR isoforms share a common structure with all nuclear hormone receptors by 
having 4 distinct domains; A/B, C, D, and E/F (Figure 7). While the A/B, activation function 1 
(AF1), and E/F, LBD and activation function 2 (AF2), domains are poorly conserved regions, 
there is a high degree of sequence and structural homology in the C, DNA binding domain (DBD) 
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and D, hinge region, domains across all isoforms.  (265).  
The highly variable AF1 region occupies the N-terminal end of the A/B domain (Figure 
7) and is involved in ligand independent gene regulation and cofactor recruitment. Upon ligand 
binding, PPARs form heterodimers with RXRs that are activated by 9-cis-retinoic acid (Fig 7), 
and regulate gene expression through a direct interaction with PPAR response elements (PPREs) 
in target gene promoters that have a direct 1 (DR-1) repeat sequence (AGGNCA A AGGTCA) 
(206, 266) (Fig 9). The PPAR DBD possesses a canonical C4 zinc finger motif, common to 
nuclear receptors. The α-helix motif in the proximal zinc finger of the P box region is involved in 
high affinity recognition of the PPRE core half site of the PPRE. The distal, D box region of the 
second zinc finger contains another α-helix that lies perpendicular to the P-box domain and 
mediates receptor dimerization (267, 268). Specificity of PPAR isoforms for target genes is 
detected when PPAR isoforms are co-expressed at similar levels in a single cell type (269), and 
 
Figure 7. PPAR structural domains.  
 
PPARs have a canonical nuclear hormone receptor structure with 4 distinct domains: N-
terminal AF1 domain (A/B), DNA binding domain (DBD) (C), hinge region (D), and 
ligand binding domain (LBD) containing the C-terminal AF2 region (E/F). Image is from 
the Nuclear Receptor Resource Website . 
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studies using chromatin immunoprecipitation sequencing and genome-wide analysis, show that 
PPARs have different affinities for specific genomic PPRE variants within target genes (269, 
270). The PPAR LBD is flanked by the highly flexible D or hinge region and AF2, ligand-
dependent activation domain, located near the C terminus (Figure 7) (271). The three PPAR 
subtypes have 60–70% amino acid sequence homology between their LBDs, resulting in a similar 
tertiary structure, composed of 13 α-helices and 4 β-sheet motifs, which fold to create a large 
(~1300Å), hydrophobic Y-shaped ligand binding pocket (272, 273).  
 
Transcriptional regulation by PPARδ 
All of the PPAR isoforms induce target gene expression in response to ligand binding; 
however, PPARδ is also a potent transcriptional repressor in the absence of ligands (274-276). 
The ability to repress or induce target gene expression is determined by ligand and co-regulator 
binding (277). PPARδ represses basal transcription of PPRE containing target genes through a 
process termed ligand-independent repression (276). In the absence of ligand, the AF2 region 
assumes a three-turn α-helix structure that favors association with corepressor molecules, such as 
nuclear receptor corepressor (NCoR) and the related silencing mediator for retinoid and thyroid 
hormone receptor (SMRT) (278, 279) (Figure 8), which form large multi-protein complexes that 
include histone deacetylases (HDACs) and transducin beta-like protein-1 (TBL1) to actively 
repress gene expression (280-282). Agonist binding induces an allosteric shift in the C-terminal 
AF2 region, revealing a leucine zipper motif located in a conserved region of the LBD that serves 
as a docking site for RXR (283, 284). RXR hetero-dimerization releases corepressors in exchange 
for LXXLL motif containing coactivators, leading to formation of the “charge clamp”, a 
transcriptionally active form of the receptor (285-287) (Figure 8). In the charge clamp 
conformation, transcriptional coactivators such as steroid receptor coactivator-1 (SRC-1) and 
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Figure 8. Steps involved in ligand-induced coregulator exchange. 
 
1.) When not bound to ligands, PPARδ associates with corepressors including nuclear 
receptor corepressor (NCoR) and silencing mediator for retinoid and thyroid hormone 
receptor (SMRT) that form large multi-protein corepressor complexes containing histone 
deacetylase (HDAC) and transducin beta-like protein-1 (TBL1) to actively repress target gene 
expression. 2.) PPAR ligand binding induces dimerization with retinoid X receptor (RXR). 
3.) PPAR:RXR heterodimer releases corepressors in exchange for coactivators, such as 
steroid receptor coactivator-1 (SRC-1) and CREB binding protein/p300 (CBP). 4.) CBP and 
SRC form a coactivator complex and recruit basal transcriptional machinery including RNA 
polymerase to the active, ligand bound PPAR: RXR heterodimer (“charge clamp” formation), 
leading to transcriptional activation and expression of target genes. Image adapted from Nolte 
et al. 1998 Nature 395, 137-143 and Perissi et al 2004. Cell 116, 511-526 . 
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Figure 9. Ligand-dependant transcriptional regulation by PPARδ:  
 
Upon ligand binding, PPARs form a heterodimer complex with 9-cis-retinoic acid receptor 
(RXR), and regulate gene expression through a direct interaction with PPAR response 
elements (PPRE) in target gene promoters (Transactivation). PPARs reduce inflammation by 
preventing other transcription factors, such as NF-KB and AP1, from binding to their DNA 
response elements (Transrepression). Image adapted from Coll et al. 2010. PPAR research. 
 . 
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CREB binding protein/p300 (CBP) bind and recruit basal transcriptional machinery to the target 
gene promoter. PPARδ can also repress the expression of non-PPRE containing genes, by 
preventing other transcription factors from associating with their DNA response elements, a 
process termed ligand dependent trans-repression (Figure 9) (288, 289). Trans-repressed genes 
include inflammatory cytokines and other targets of NF-κB as well as gene targets of the 
transcription factor, activator protein 1 (AP1) (290).  
 
PPARδ ligands 
PPAR isoforms have different affinities for ligands due to differences in structure as well 
as charge of individual amino acids within the ligand binding pocket (291). PPAR ligands were 
first identified through the use of several different ligand screening assays which provided 
functional evidence that long-chain fatty acids (LCFA), prostaglandins, leukotrienes and 
eicosanoids were PPAR ligands (Table 1) (206, 292, 293). In one assay, ligands were screened 
for the ability to induce formation of the PPAR:RXR heterodimer, and  activation of a consensus 
PPRE sequence fused to a luciferase reporter gene (292). Another functional assay was used to 
screen ligands for the ability to induce coactivator recruitment, which is a critical step for 
transcriptional activation (293). Crystallography and radioligand displacement helped consolidate 
findings from these two methods, as well as to provide quantitative affinities of fatty acids for 
PPAR LBDs (294). Data from these studies showed that LCFA can bind all PPAR isoforms with 
various affinities (292, 293, 295) (Table 1). PPARα has a highly hydrophobic LBD and binds 
SFAs (C14-C16) with high affinity (1.1–5.4 μM) in vitro (295) and in vivo (243). SFAs bind with 
slightly less affinity to the PPARδ LBD (295), but do not activate expression of a PPARδ reporter 
construct to any significant degree (292). 
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Chemical ligands include L-165041, a potent PPARδ agonist with 100-fold selectivity 
over other subtypes (300), and with 1000-fold greater selectivity, GW0742 and GW501516 (214, 
301). GSK0660 is a potent selective inverse agonist with 100-fold selectivity over other isoforms 
(299). GW0742 and GSK0660 were utilized in cell culture and in vivo experiments described in 
this dissertation. 
 
PPARδ: Roles in obesity and metabolic disease 
Genetic mutations of PPARδ 
Genetic mouse models have been used to study the function of PPARδ in development, 
metabolism and disease in mice. Constitutive deletion of the N-terminal half of the DNA binding 
domain (221) led to over 90% embryonic lethality of knockout animals, whose death were due to 
Table 1. PPARδ ligands 
Ligand Comment Reference 
Oleic acid 
 (C18:1) 
MUFA, agonist (PPARδ/PPARα/PPARγ) 
(237, 293, 
296, 297) 
Linoleic acid (C18:2) MUFA, agonist (PPARδ/PPARα/PPARγ) 
(292, 293, 
295) 
Linolenic acid (C18:3) PUFA, agonist (PPARδ/PPARα/PPARγ) 
(293, 295, 
298) 
Arachidonic acid  
(C20:4) 
PUFA, agonist (PPARδ/PPARα/PPARγ) 
(292, 293, 
295) 
Docosahexaenoic Acid 
(C22:6) 
PUFA, agonist (PPARδ/PPARα) (292, 293) 
GW0742 and 
GW501516 
Potent, selective chemical agonist (PPARδ) 
1000-fold selectivity 
(214) 
L165,041 
Selective chemical agonist (PPARδ), 100-fold 
selectivity 
(292) 
Palmitic acid (C16:0) 
SFA, non-agonist ligand (PPARδ) 
Agonist (PPARα) 
[47]  
GSK0660 
Highly selective antagonist (PPARδ), 100-fold 
selectivity 
(299) 
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placental defects. Surviving knockout animals were smaller and had little brown or white adipose 
tissue on chow diet, but became profoundly obese when placed on a high fat diet (302). Deletion 
of the C terminal 60 amino acids, which encompasses part of the LBD and the AF2 region of the 
protein was not lethal, but mice exhibited abnormal growth, reduced adipose and skin defects 
(303, 304) with alterations in brain lipid metabolism.  
To avoid the high rate of embryonic lethality of the global deletion mutant, a conditional 
“floxed” allele with lox-P sites flanking exon 4 (DBD encoding region) has been utilized to delete 
PPARδ in a tissue specific manner (221). Deletion of PPARδ in cardiomyocytes leads to reduced 
basal expression of fatty acid oxidative genes, cardiomyopathy and lipotoxicity (305). Inducible 
deletion of the same floxed allele in heart reduced the expression of genes involved in 
mitochondrial biogenesis and function, supporting a role for PPARδ in mitochondrial function 
(234). The conditional allele has also been deleted in a number of tissues (reviewed in (306)), 
including skeletal muscle, where genetic deletion results in lipotoxicity, insulin resistance and 
obesity (307).  
 
Effects of PPARδ agonists on lipotoxicity and insulin resistance  
Agonists of PPARδ oppose HF diet-induced inflammation and insulin resistance in vivo, 
and reduce palmitate induced lipotoxicity and insulin resistance in vitro (Table 2). These 
protective effects of chemical agonists to prevent inflammation may be mediated by induction of 
several PPARδ target genes involved in mitochondrial fatty acid oxidation and uncoupling (231, 
234, 236, 238, 308). Agonist treatment is also associated with reductions in mRNA levels of the 
NF-κB target genes, IL-6 and IL-1β, whose expression are induced by palmitate exposure (231, 
308) , which improves insulin sensitivity (231, 307, 309-311). As a whole, these studies suggest 
that PPARδ agonists should reduce inflammation and improve hypothalamic insulin sensitivity; 
and therefore, neuronal PPARδ may be an attractive pharmacological target in the treatment of 
DIO.  
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Rationale and Hypothesis 
Consumption of a HF diet has been shown to lead to inflammatory signaling in key 
neuronal subsets involved in the regulation of energy homeostasis (74, 133, 137, 313) resulting in 
behavioral and biochemical resistance to insulin, leptin and other regulatory hormones and 
nutrient signals in the CNS. MUFAs in the diet are beneficial and improve insulin sensitivity 
(187-192). Diets rich in MUFAs are also less obesogenic than those high in SFAs (184-186). The 
MUFA oleate has anti-inflammatory properties and can prevent palmitate induced insulin 
resistance in skeletal muscle cells (314-316). This suggested that substitution of SFAs with 
MUFAs in the diet may offer some protection against the development of DIO related 
hypothalamic inflammation as well. 
My dissertation work has focused on understanding how different types of dietary fats 
modulate the signaling events that lie upstream of inflammation and CNS hormone resistance. 
Chapter III explores how dietary fat composition influences the development of DIO related 
Table 2. Effects of PPARδ agonists on lipotoxicity and insulin resistance 
 Effect Comment System  
Ischemia and 
GW0742 
Increase cardiac fatty acid 
oxidation, prevent 
apoptosis and improve 
insulin sensitivity 
Reduce expression: IL-
6, MCP1, IL-8, and 
ICAM-1  
Zucker 
fatty rat, 
heart 
(309) 
GW501516 
and HFD or 
palmitate 
Reduce inflammation and 
prevent hypertrophy 
Reduce expression: 
TNFα, MCP-1 and IL-6  
Mouse 
heart, 
cardiac 
cells 
(308) 
Palmitate and 
GW501516 
Reduce inflammation, 
prevent DAG and PKC 
accumulation, and improve 
insulin sensitivity  
Increase expression: 
CPT-1 and PDK4. 
 Reduce expression: IL-
6  
Skeletal 
muscle 
cells 
(231) 
Palmitate and 
GW501516 
Reduce inflammation 
(JNK) 
Increase expression: 
Maf-A and GLUT2  
Pancreatic 
β-cells 
(312) 
Palmitate and 
GW501516 
  
Maintain mitochondrial 
function and prevent 
apoptosis 
Increase expression: 
CPT-1, LCAD, PDK4 
and UCP2  
Pancreatic 
β-cells 
(238) 
Palmitate and 
GW501516 
Maintain mitochondrial  
function 
Increase expression: 
PGC1a, NRF-1, mtTFA 
and UCP2. 
Pancreatic 
β-cells 
(236) 
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hypothalamic inflammation and insulin resistance. The protective effects of MUFAs have been 
attributed to a diverse group of “fatty acid sensor” molecules that bind fatty acids. Of these, 
PPARδ was a likely candidate based on its high expression in the CNS, its ability to regulate 
genes that increase fatty acid oxidation, mitochondrial biogenesis and induce mitochondrial 
uncoupling. Additionally, chemical agonists of PPARδ are protective against palmitate induced 
inflammation and insulin resistance in peripheral tissues, have neuroprotective and anti-
inflammatory effects and attenuate oxidative stress in the CNS. This evidence supported two 
complementary hypotheses, the first being that circulating or endogenous fatty acids act as 
ligands and activate neuronal PPARδ to increase expression of its target genes in neurons. The 
literature also supports a second hypothesis, that PPARδ is a protective MUFA sensor, which 
opposes lipotoxicity and supports insulin and leptin sensitivity in hypothalamic neurons, and 
provides protection from DIO (Figure 10). The results of experiments directly testing these 
hypotheses in an immortalized hypothalamic neuronal cell line, treated with different 
combinations of a SFA and MUFA, as well as selective chemical ligands of PPARδ to directly 
probe the interaction between fatty acids and PPARδ are described in chapter IV.  
 
 
Figure 10. Hypothesis: PPARδ is a protective monounsaturated fatty acid sensor in 
neurons. 
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Chapter V investigates the effects of PPARδ deficiency on energy balance, DIO, 
hypothalamic inflammation and hypothalamic gene expression. A genetic deletion mouse model 
was used to test the hypothesis that loss of PPARδ would cause CNS stress and inflammation, 
insulin and leptin resistance and increased susceptibility to obesity. A summary of the results 
from these studies is contained in chapter VI and placed in context of what is known about the 
PPAR family of receptors in the CNS, as they relate to energy balance, as well as suggested paths 
of future research. 
36 
 
CHAPTER II 
 
MATERIALS AND METHODS 
 
Experimental animals: rats 
Eucaloric high-fat diets 
Male, Long Evans rats (Harlan; Indianapolis, IN) were acclimated to a purified control 
diet with LF content (kcal%: fat 10%, carb 70%, protein 20%) (D12450B, Research Diets; New 
Brunswick, NJ) (Table 3). All animals were housed in a temperature (22 ˚C) and light (12 hour 
light/dark cycle) controlled room with free access to food and water except where indicated. 
Body weight and food intake were measured on a standard balance. Body composition was 
measured by nuclear magnetic resonance (NMR)/magnetic resonance imaging (MRI) in a Body 
Composition Analyzer (Echo MRI; Houston, TX). Rats were randomized into groups based on 
adiposity (fat mass/total body weight x 100) and housed in pairs to receive LF control diet or one 
of two micronutrient matched HF diets containing 45% of total calories as fat (45% fat, 35% carb, 
20% protein) but different fatty acid compositions, one enriched in SFAs (formulated from lard: 
HF-SFA; Research Diets, D12451) and the other a custom formulated diet enriched in MUFAs 
(formulated from high-oleic safflower oil: HF-MUFA; Research Diets) (Table 3).  
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ICV surgery and administration of GW0742 
Male, Long-Evans rats weighing 300-350 g underwent third ventricle cannulation. Rats 
were placed in a Stoelting stereotaxic apparatus (Stoelting Co; Wood Dale, IL) and the head 
secured and prepared for sterile surgery. A 1 cm incision was made at the apex of the skull, and a 
small piece of bone (2 mm x 2 mm) was gently removed using a battery powered drill. A 22-
gauge fused silica guide cannula (#C313G/FS; Plastics One; Roanoke, VA) fitted with a plastic 
internal cannula (#C313I/PK; Plastics One; Roanoke, VA) was inserted into the third ventricle 
using coordinates; anteroposterior, 0.2 mm; lateral, 1.5 mm; depth, 4.0 mm. The device was fixed 
to the skull with three nylon mounting screws and acrylic cement. Following a 7 day recovery 
period, rats were randomized to receive an ICV bolus of vehicle (in 2 µL dimethyl sulfoxide 
(DMSO)) or the PPARδ agonist GW0742 (4-[2-(3-fluoro-4-trifluoromethylphenyl)-4-
methylthiazol-5-ylmethylsulfanyl]- 2-methylphenoxy)-acetic acid; Cayman Chemical; Ann 
Arbor, Michigan) (50 µg total in 2 µL DMSO). After 24 hours, rats were anesthetized by CO2 
inhalation, and were euthanized by decapitation.  
Table 3. Experimental high-fat diets 
 D12450B D12451 __________ 
Fatty acids LF (10%) HF-SFA  (45%) HF-MUFA (45%) 
C14:0 0.8 (0.1) 0.8 (0.4) 0.1 (0.0) 
C16:0 22.6 (2.3) 22.6 (10.2) 5.8 (2.6) 
C18:0 12.9 (1.3) 12.9 (5.8) 2.0 (0.9) 
Σ SFA 36.3 (3.6) 36.3 (16.3) 8.3 (3.8) 
C16:1 3.5 (0.4) 3.5 (1.6) - 
C18:1ω9 41.3 (4.1) 41.3 (18.6) 71.4 (32.1) 
Σ MUFA 45.3 (4.5) 45.3 (20.4) 71.7 (32.2) 
C18:2 ω6 14.9 (1.5) 14.9 (6.7) 19.1 (8.6) 
C18:3 ω3 1.9 (0.2) 1.9 (0.9) 1.0 (0.4) 
C20:4 ω6 1.6 (0.2) 1.6 (0.7) - 
C22:6 ω3 - - - 
Σ PUFA 18.5 (1.8) 18.5 (8.3) 20 (9.0) 
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Effects of high-fat diet on hypothalamic oxidative stress  
Male, Long Evans rats (Harlan; Indianapolis, IN) were housed individually and 
acclimated to IP injections (saline, 2 mL) for 7 days. A LF control diet (Table 3) was 
administered during the acclimation period. Rats were randomized into groups based on adiposity 
to receive LF control diet or HF diet (Table 3). Groups of LF and HF fed rats received the 
mitochondria targeted antioxidant MitoTEMPO (2-(2,2,6,6-Tetramethylpiperidin-1-oxyl-4-
ylamino)-2-oxoethyl)triphenylphosphonium chloride monohydrate) (Alexis; San Diego, CA) 
(1.5mg/kg/day, IP) or vehicle (saline). Fresh solutions of MitoTEMPO were prepared every two 
days in saline and stored at 4 C. After 7 days, rats were fasted for 4 hours then received heparin 
(1U/kg, IP), were anesthetized by CO2 inhalation, and were euthanized by decapitation. 
 
Experimental animals: Mice 
Neuronal PPARδ knockout model 
Transgenic mice were obtained from Jackson Laboratories (The Jackson Laboratory; Bar 
Harbor, Maine) and were backcrossed to a C57Bl6 background for greater than 6 generations. 
Mice homozygous for a conditional allele of PPARδ, containing Lox P sites flanking exon 4 of 
the PPARδ gene (B6.129S4-PPARδtm1Rev/J) (302) (Figure 11) were mated with mice that 
express Cre recombinase under the control of the rat nestin promoter (317) (B6.Cg-Tg (Nes-
cre)1Kln/J) (The Jackson Laboratory). These crosses resulted in heterozygous offspring 
(PPARδf/wtNestin-cre+/-), which were mated together, or crossed to PPARδf/f mice to produce 
neuronal PPARδ knockout mice, referred to as KO (PPARδf/f cre +) and “floxed” littermate (f/f) 
control mice (PPARδ f/f or PPARδf/wt).  
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Diet-induced obesity  
Baseline body weight and body composition was assessed at 5 weeks of age. Mice were 
grouped by genotype and housed 3 to a cage. PPARδ KO mice and their litter mate controls were 
studied on LF and HF diet (Table 3). Body weight and food intake were measured using a 
standard balance, and body composition was measured with the Minispec TD-NMR Body 
Composition Analyzer (Bruker Optics; Billerica, MA).  
 
Indirect calorimetry 
Energy expenditure (EE) was assessed by indirect calorimetry in 12-week-old chow fed 
mice and after 20 weeks on HF diet. Mice were housed individually in Oxymax cages (Columbus 
Instruments; Columbus, Ohio). VO2 and VCO2 (mL/hr) were measured after a 24 hour 
 
Figure 11. PPARδ lox-P knock-out model.  
CNS deletion of PPARδ was achieved using mice that express a “floxed” PPARδ allele 
containing Lox P recognition sites flanking exon 4, which encodes the amino terminal portion 
of the DNA binding domain of the protein (Figure 7). Nestin-Cre mediated recombination 
leads to excision of 160 bp region of DNA containing exon 4 region resulting in a mutated 
protein that lacks a 51 amino acid,  ~5.24 kb region of the DNA binding and hinge region, 
and hence does not bind DNA. 
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acclimation period and calculated based on the input and output rates of O2 consumption and CO2 
production. The RER (RER=VCO2/VO2) and heat production (kcal/hr = (3.815 + 1.232 x RER) x 
(VO2)) were calculated using software provided by the manufacturer (Columbus Instruments; 
Columbus, Ohio). EE data (kcal/hr) were normalized to body weight (g) and also lean mass (g) as 
measured by NMR on the day mice were placed in the chambers. 
 
Glucose tolerance test 
Glucose tolerance testing was performed in 12-week-old chow fed mice and after 20 
weeks on HF diet. Mice were fasted for four hours prior to receiving an IP glucose bolus injection 
(D-glucose, 1 g/kg body weight in 200 μL saline). Blood glucose was measured using a Freestyle 
handheld glucometer (Abbott Labs; Abbott Park, IL) in blood obtained from a small incision 
made at the tip of the tail with a sterile razor blade. Readings were made at baseline and at 5, 15, 
30, 60, 90 and 120 minutes after glucose was administered. 
 
Leptin sensitivity 
To assess behavioral leptin sensitivity, individually housed, male, KO and f/f control 
mice were acclimated to IP injections (saline, 300 µl) for 7 days. On the day of the study, food 
was withdrawn at 2 PM and mice were fasted for 4 hours. A known quantity of food was placed 
in the cage at 6 PM, at which time mice received an IP injection of vehicle (0.3 mL saline) or 
leptin (5 μg/g body weight) (ProSpec; East Brunswick, NJ). Total caloric intake and food intake 
normalized to body weight were determined for the 24 hour period after leptin treatment. Cellular 
leptin sensitivity was assessed in a second group of mice treated similarly. Hypothalami were 
collected 30 minutes after leptin was injected and processed for immunological detection of 
STAT3 phosphorylation by Western blot analysis (see below). 
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Fasting-refeeding challenge 
The effects of fasting on body weight, food intake and hypothalamic gene expression of 
NPY, POMC and UCP2 were determined in chow fed male, KO and f/f mice. To assess changes 
on body weight, body composition and food intake after prolonged fasting, mice were housed 
individually. On the day of the study, baseline body weight and body composition were measured 
and food was withdrawn at 10 AM. Mice were fasted for 24 hours and the measurements were 
repeated at the end of the fasting period. Food intake and weight gain were measured over a 24-
hour refeeding period during which mice had free access to chow diet. Hypothalamic 
neuropeptide gene expression was determined in a second group of f/f and KO mice. Mice were 
given ad libitum access to chow diet, or fasted for 24 hours beginning at 10 AM. After 24 hours, 
both the fasted and fed groups of mice were anesthetized by isoflurane inhalation and euthanized 
by decapitation.   
 
Hypothalamic-pituitary-adrenal axis function  
HPA axis function was assessed in 12-week old, single-housed, chow-fed mice. Nadir 
blood samples (>100 μL) were collected from the submandibular vein at 8 AM, and in a similar 
manner, peak samples were taken at 5 PM three days later. Stress induced corticosterone levels 
were measured after another 3 day recovery period. Mice were subjected to one minute of mild 
handling stress, returned to their home cages for 30 minutes, after which blood was collected via 
the submandibular vein. Only individual samples that were collected within one minute were 
included in the analysis. 
 
Histology 
Mice were anesthetized with sodium pentobarbital (60 mg/kg) and given heparin (1 
U/kg). A vertical incision was made along the midline of the chest, and then mice were 
transcardially perfused with 250 ml of 4% formaldehyde in phosphate buffered saline (PBS; 0.1 
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M, pH 7.4). Brains were removed and post-fixed overnight in 4% formaldehyde. Coronal sections 
at 40 μm were made with a freezing microtome, sections were mounted on gelatin coated slides, 
and stained with Nissl stain (0.1% cresyl violet) (318). Epididymal white fat tissue samples were 
collected from chow fed mice and after 33 weeks of HFD exposure, fixed for 24 hours in 4% 
paraformaldahyde, then transferred to 70% ethanol before paraffin embedding and hematoxylin 
and eosin (H&E) staining (Vanderbilt Histology Core). Series of nonadjacent sections were 
processed for each staining protocol. Images were collected at 10x magnification using bright 
field light microscopy and qualitatively examined by an experimenter blinded to genotype. 
 
Medial basal hypothalamus wedge dissection 
Brains were rapidly removed and flash frozen under powdered dry ice and coronally 
sectioned at the optic chiasm and the rostral edge of the pituitary stalk. A wedge containing the 
arcuate nucleus, ventral and dorsal medial nucleus, and medial edge of the lateral hypothalamus 
were dissected with a razor blade, rapidly frozen and stored at -80 ˚C. 
 
Hypothalamic neuronal cell culture 
Cell culture conditions 
Clonal mouse hypothalamic mHypoE-N42 (319) neuronal cells were obtained from 
Cedarlane Laboratories Ltd. (Burlington, Ontario Canada). Cells cultured in 150 cm
2
 flasks and 
maintained at 37 °C with 5% CO2 in low-glucose Dulbecco's Modified Eagle Medium (DMEM) 
growth media (D-glucose, 1 g/L; L-glutamine, 0.584 g/L; sodium bicarbonate, 3.7 g/L; and 
pyruvate, 110 mg/L) with 10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen, 
Grand Island, NY). Experimental treatments were performed on cells plated in 100 mm culture 
plates.   
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Chemical reagents 
Stock solutions (2 mM) of the PPARδ agonist GW0742 (Cayman Chemical; Ann Arbor, 
MI) and the PPARδ antagonist GSK0660 (3-[[[2-Methoxy-4-
(phenylamino)phenyl]amino]sulfonyl]-2-thiophenecarboxylic acid methyl ester; Sigma Aldrich; 
St. Louis, MO) (299) were prepared in DMSO and stored at -20 °C. Cells were treated with 
vehicle (0.05% DMSO) or chemical PPARδ ligands at final concentrations of 1 nM (GW0742) or 
1 μM (GW0742 or GSK0660) for 24 hours.  
 
Fatty acid treatment in cell culture 
Stock solutions (100 mM) of palmitate (C16:0) and oleate (C18:1) (Sigma Aldrich; St. 
Louis, MO) were prepared in 0.1 N NaOH (70 ˚C for 30 minutes). Concentrated stock solutions 
of fatty acids (FFA) were added to a solution of ultra-pure, fatty-acid-free, bovine serum albumin 
(10%, cell culture grade water) (Sigma Aldrich; St. Louis, MO), and left at room temperature for 
30 minutes to allow FFA:BSA conjugation. Serum-free DMEM was added to give a final 
concentration of either FFA at 100 μM with excess BSA (150 μM) (final FFA:BSA ratio of 
0.67:1). To determine if PPARδ protects neurons from FFA induced lipotoxicity in DIO, the 
concentration of BSA was held at 100 µM and mHypoE-N42 cells were treated with a mixture of 
oleate 100 μM and palmitate 250 μM (FFA:BSA ratio of 3.5:1) with or without the PPARδ 
inhibitor GSK0660 (1 μM).  
 
Insulin signaling in cell culture 
Following treatment with FFAs, cells were stimulated with recombinant human insulin 
(10 nM, 5 minutes) (Sigma Aldrich; St. Louis, MO). Media was rapidly removed, and cells were 
rinsed with ice cold PBS, harvested by scraping directly into protein extraction buffer and 
immediately frozen on dry ice.   
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Molecular and biochemical techniques 
Genotyping of mice 
Genotyping of mice for the “floxed” PPARδ allele and Nes-Cre transgene was performed 
by PCR using DNA extracted from tail clippings (1-2 mm) by the Hot Shot method (320). 
Clippings were heated in an alkaline lysis reagent (100 μL, 25 mM NaOH, 0.2 mM EDTA, pH 
12) on a heat block (90 °C, 25 minutes) with constant shaking, after which an equal volume of 
neutralization reagent (40 mM Tris HCL. pH 5) was added. PCR was performed with 2 uL of 
DNA using 5Prime PCR Supermix (5Prime; Gaithersburg, MD) (annealing temperature 65   C, 40 
cycles) and appropriate PCR primers for the floxed PPAR δ allele (common: 5’ GAG CCG CCT 
CTC GCC ATC CTT TCA G 3’ and wild type 5’ GGC GTG GGG ATT TGC CTG CTT CA 3’) 
as well as for the nestin cre transgene ( 5’ GCG GTC TGG CAG TAA AAA CTA TC 5’ and 5’ 
GTG AAA CAG CAT TGC TGT CAC TT 3’ ) (annealing temperature 57 °C, 40 cycles). The 
amplified cDNA was separated by electrophoresis on an agarose gel (nestin, 1%; agarose; 
PPARδ, 2.5% agarose; 0.5 g/mL ethidium bromide (EtBr), 1X Tris-acetate (TAE) composed of 
40 mM Tris (pH 7.6), 20 mM acetic acid, and 1 mM ethylenediaminetetraacetic acid (EDTA)) 
followed by ultraviolet detection of bands stained with EtBr. Mice were genotyped based on the 
presence of expected PCR products for the PPARδ allele; homozygous floxed mutant (400 bp), 
heterozygotes (359 bp and 400 bp) and wild type mice (359 bp). A single band (100 bp) indicated 
the presence of the Nestin-Cre transgene.  
 
Measurements of plasma hormones and metabolites  
Trunk blood was collected into EDTA treated 3 ml tubes and plasma was separated by 
centrifugation (20 min, 4 ˚C, 1,500 xg) then stored in 1.5 mL tubes at -80 °C. Plasma levels of 
insulin, leptin and corticosterone were quantified by radioimmunoassay by the Vanderbilt 
Diabetes Center Hormone Assay Core. Plasma triglycerides and free fatty acid levels were 
determined by enzymatic assay (Waco Chemicals; Richmond, VA).  
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Brain and plasma free fatty acid composition analysis  
Lipids were extracted from whole brain or plasma using the method of Folch-Lees (321). 
The extracts were filtered, and lipids recovered in the chloroform phase. Individual lipid classes 
were separated by thin layer chromatography using Silica Gel 60 A plates (Sigma Aldrich; St. 
Louis, MO) developed in petroleum ether, ethyl ether, acetic acid (80:20:1), and visualized by 
rhodamine 6G. Diglycerides and triglycerides were scraped from the plates and methylated using 
BF3/methanol as described by Morrison and Smith (322). The methylated fatty acids were 
extracted and analyzed by gas chromatography. Gas chromatographic analyses were carried out 
on an Agilent 7890A gas chromatograph (Agilent; Santa Clara CA) equipped with flame 
ionization detectors, a capillary column (SP2380, 0.25 mm x 30 m, 0.25 µm film, Supelco, 
Bellefonte, PA). Helium was used as a carrier gas. The oven temperature was programmed from 
160 °C to 230 °C at 4 °C/min. Fatty acid methyl esters were identified by comparing the retention 
times to those of known standards. Inclusion of lipid standards with odd chain fatty acids 
permitted quantitation of the amount of lipid in the sample.  
 
Western blot analysis 
Frozen tissues or cultured cells were sonicated in cold TPER buffer (10 μL/mg tissue) 
with added protease and phosphatase inhibitors (Promega; Madison, WI) with a Q55 Sonicator 
(Misonix Sonicators; Newton, CT) (setting 3, <10 seconds). Protein levels were measured with 
the Micro BCA Protein Assay Kit (Thermo Scientific; Rockford, IL). Diluted protein samples (1 
mg/mL) were mixed with 4X Sample Buffer and 20X Reducing Agent (Bio-Rad; Hercules, CA), 
heated to 85 °C for 10 min, and immediately loaded into a well on a gel (20 μg total protein per 
lane) along with a Kaleidoscope Precision Plus Protein Standard (Bio-Rad; Hercules, CA). 
Samples were subjected to denaturing electrophoresis on a 4-12% Tris Acetate gel with XT 
Tricine Running Buffer using the Bio-Rad XT Criterion System (Bio-Rad; Hercules, CA). Protein 
was transferred to 0.2 μm nitrocellulose or 0.45 µm polyvinylidene fluoride (PVDF) (Millipore; 
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Billerica, MA) membranes using the Criterion Blotter module, according to the manufacturer’s 
instructions (Bio-Rad; Hercules, CA). Membranes were blocked in Starting Block T20 Blocking 
Buffer (Thermo Scientific, Rockford, IL) for 1 hour at room temperature and incubated in 
primary antibodies (diluted 1/1000) in blocking buffer at 4 °C with gentle rocking overnight. 
Blots were washed in TBS-T (Tris Buffered Saline; 150 mM NaCl, 20 mM Tris pH 7.5 with 0.1 
(v/v) Tween 20 (Sigma Aldrich; St. Louis, MO) for (3 x 10 minutes) at room temperature, and 
incubated with species specific horse radish peroxidase-conjugated secondary antibody in 50/50 
blocking buffer and TBS-T for 1 hour at room temperature and washed in TBS-T (3 x 10 
minutes). Antibody detection was performed with ECL Enhanced Chemiluminescence Substrate 
Kit (Amersham Biosciences; Piscataway, NJ) and BioMax XAR scientific imaging film (Kodak; 
Rochester, NY). Band intensity from X-ray film detection was analyzed by densitometry using 
ImageJ software from the National Institutes of Health. 
Primary antibodies used for immunological detection were: anti-p(Y705)Stat3 (#2687, 
Cell Signaling; Danvers, MA), anti-p(T980)PERK (#3179, Cell Signaling), anti-p(S473)Akt 
(#9271, Cell Signaling), anti phosphorylated p66 Src homology 2 domain containing 
transforming protein (p66shc) p(S36)p66shc (6E10, Santa Cruz; Santa Cruz, CA), anti-IκBα 
(#9242, Cell Signaling), anti-PERK (#3192, Cell Signaling), anti-STAT3 (#4904, Cell Signaling), 
anti-β-tubulin (#2146,Cell Signaling), heat shock cognate protein 70 (HSC70) (K-19, Santa Cruz) 
and anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (#2118, Cell Signaling). 
Secondary antibodies used for immunoblotting included: horseradish peroxidase-conjugated goat 
anti-rabbit IgG (1:5000; W401B, Promega; Madison, WI) and bovine anti-goat IgG (1:7500; sc-
2350 Santa Cruz; Santa Cruz, CA). 
 
Real-time PCR  
Total RNA was extracted from brain tissues using the RNAqueous kit (Ambion; Austin, 
TX) or from confluent, 100 mm cell culture plates using Trizol (Invitrogen; Grand Island, NY). 
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RNA was precipitated with an equal volume of lithium chloride (1:1 dilution, 7.5 M LiCl), 
mixed, stored at -20 °C overnight, and the pellet collected by centrifugation (13,000 xg, 20 
minutes, 4 °C). The pellet was washed with 70% ethanol, allowed to dry, and after which, RNA 
was re-suspended in a small volume (~20μl) of ultra-pure molecular biology grade water. Sample 
RNA concentrations were quantified on a Nanodrop 1000 spectrophotometer (Nanodrop; 
Wilmington, DE). RNA integrity was determined using a total of 2 µg of RNA by electrophoresis 
on a agarose gel (1.5% agarose, 0.5 µg/mL EtBr, 1X TAE) followed by UV detection of 28S, 18S 
and 5S RNA stained with EtBr. A cDNA template was synthesized from equal amounts of each 
sample of RNA (1-2 µg) using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems; Carlsbad, California). Target gene mRNA expression was analyzed with iQ SYBR 
green Supermix reagent (Bio-Rad; Hercules, CA) by real-time PCR (RT-PCR) on an iCycler PCR 
machine (Bio-Rad; Hercules, CA). Standard curves (six-point serial dilution) were generated 
using cDNA synthesized from XpressRef
TM
 mouse universal total RNA (SuperArray Bioscience; 
Frederick, MD) and used to calibrate relative quantification of product in the exponential phase of 
the amplification curve in all experiments at 95-105% amplification efficiency. Target gene 
expression was normalized to endogenous expression of the internal control 60S ribosomal 
protein L13A (RPL13A). Real time primers were previously published or designed using Beacon 
Designer (Beacon Design Software; Palo Alto, CA) (Vanderbilt Molecular Cell Biology Resource 
Cores) (Table 4).  
 
Detection of superoxide production in rat hypothalamus 
Hypothalami were dissected into quarters in ice cold Krebs HEPES buffer (99mmol/L 
NaCl; 4.7mmol/L KCl; 1.2mmol/L MgSO4; 1.0mmol/L KH2PO4; 1.9mmol/L CaCl2; 25mmol/L 
NaHCO3; 11.1mmol/L glucose; 20mmol/L NaHEPES). Mitochondria derived superoxide levels 
were determined by HPLC using the fluorescent probe MitoSOX (Excitation/Emission: 510/580 
nm, Invitrogen; Carlsbad, CA). Samples were supplemented with 4 µM MitoSOX for 20 minutes 
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and then washed with Krebs/HEPES buffer. The cells were then harvest in methanol for 
extraction of 2-OH-Mito-E
+
 and Mito-E
+
. HPLC analysis of the superoxide specific product of 
MitoSOX (2-OH-Mito-E
+
) was performed by the Free Radicals in Medicine Core Laboratory. 
 
Detection of intracellular H2O2 derived oxidant production 
Intracellular ROS levels were measured using the membrane permeable H2O2 specific 
dye 2′,7′-Dichlorofluorescein diacetate (DCFH-DA) (Invitrogen, Grand Island, NY). Cells were 
grown in the presence of GSK0660 (1µM), GW0742 (1µM), or vehicle (0.05% DMSO) for 24 
hours. Fatty acids (oleate 100 µM, palmitate 250µM or both) were added during the last 4 hours.  
Cells were incubated with DCFH-DA (100 µmol/L) for 30 minutes, rinsed with PBS then 
florescence was recorded on the Infinite 200 PRO 96-well plate reader using excitation/emission 
wavelengths of 485nm/530nm (Tecan; Männedorf Switzerland). Intracellular levels of 
hydroxyperoxides were calculated as fluorescence intensity minus background fluorescence, 
normalized to the amount of total protein, as measured by the Micro BCA Protein Assay Kit 
(Thermo Scientific; Rockford, IL). 
 
Statistical Analysis 
Data are reported as the group mean ± SEM. Statistical analysis of differences was 
analyzed by one-way analysis of variance (ANOVA) followed by post-hoc Tukey’s multiple 
comparison test or two-way ANOVA (to assess diet x genotype interactions) followed by post 
hoc Bonferroni’s multiple comparison test, using Prism version 5.0 for Windows (GraphPad; San 
Diego, CA). The student’s t-test for non-paired values was performed when two groups were 
compared. A p value <0.05 was considered significant.  
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Table 4. Primers used to detect gene specific mRNA levels by RT-PCR 
RT-PCR Primers 
Gene Sense 5’-3’ Antisense 5’-3’ 
PPAR α TGTCGGGATGTCACACAATGC TTCAGGTCGTGTTCACAGGTAAAG 
PPARδ GGATTTTAGAGTGGGTGTTTTTTA CACACCCGATTCCATGTTGAG 
PPARγ TGGTTATTTTGTAGGTTGGTTT TTGATCGCACTTTGGTATTCTTGG 
LPL GGAGAGTTATTTAAGAAAGGTGG AGTCAGGCCAGCTGAAGTAGGAGT 
CPT1A AACACCATCCACGCCATACTG TCCCAGAAGACGAATAGGTTTGAG 
UCP2 TAAAGGTTAAGGTGTAAGGAAAATTAAG GCAATGGTCTTGTAGGCTTCG 
GPAT GGTTAAAGAATTAAATTTTGTT ACAGAATGTCTTTGCGTCCA 
SCD-1 GAGGGTAGTAAATTTGTTGGT CCCAGTCGTACACGTCATTTT 
ACC TTTGTTGGTGTTGGGATTTATAG GTCATTACCATCTTCATTACCTCAATCTC 
ACO GGATTTTTTGTAGGAAGGAGA CCACTCAAACAAGTTTTCATACACA 
FAS TTAGTGATTGGAGTAGAGAGAAGTTG ACAGAGGAGAAGGCCACAAA 
DGAT2 AGGGGTTTTTTTTAAGGTTTTTTTT AATAGGTGGGAACCAGATCAGC 
PDK4 GGGTTATAGGATGGATTGAG CATGGAACTCCACCAAATCCA 
NPY GGATAGTTGGTAGTGTTAAAGATTT AATCAGTGTCTCAGGGCTGGA 
POMC GAATTTTTTTTGGGGATTAGGG GCGAGAGGTCGAGTTTGCA 
TNFα AGAGAGGTTGTTAGGAGTTTGGT CTCCTCTGCTTGGTGGTTTG 
IL-6 TTTTAAAGGAGTTTTTGGAAAAG GCATCATCGTTGTTCATAC 
IKBα AGTTTGGTTAATAAGGGTGAGG CAAAGTCACCAAGTGCTCCACGAT 
IL-1β GGAAAATTTTTTTAGGAGGTGATT GATCCACACTCTCCAGCTGCA 
CD36 AATTAGTAGAACCGGGCCAC CCAACTCCCAGGTACAATCA 
RPL13A AGATGCACTATCCAAGA AGTCTTTATTGGGTTCAC 
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CHAPTER III 
 
DIFFERENTIAL EFFECTS BETWEEN HIGH-FAT DIETS ENRICHED IN 
MONOUNSATURATED AND SATURATED FATS AND A ROLE FOR NEURONAL 
PPARδ 
 
Introduction 
Adoption of a Western-style diet, rich in calories and saturated fat, is associated with the 
increased prevalence of obesity that occurred over the last 40 years (4, 30, 323). Current 
hypotheses suggest dietary lipid consumption induces pathophysiological changes in systems 
controlling energy balance within the CNS (32). Neurons within the mediobasal hypothalamus 
regulate energy balance in response to circulating levels of nutrients and hormones (41, 324). 
Although the molecular mechanisms leading to impaired energy balance regulation are not 
completely understood, evidence from rodent models of DIO indicates that HF diets are 
associated with hypothalamic inflammation and neuronal resistance to insulin and leptin action 
(133, 137, 325).  
Nutrient excess leads to elevated circulating FFA levels that promote lipid accumulation, 
oxidative stress and inflammation, collectively termed lipotoxicity (326, 327). The cytotoxic 
effects of SFAs involve several cellular organelles and metabolic processes including ER stress, 
mitochondrial dysfunction, and accumulation of proinflammatory bioactive lipids; all of which 
can promote insulin and leptin resistance by activating proinflammatory signaling through any 
one of several signaling pathways (182, 328-330). Our group and others have shown that DIO is 
associated with hypothalamic insulin and leptin resistance, and activation of an inflammatory 
pathway involving NF-κB, IκBα and IKKß (133, 152). This pathway has also been implicated in 
TLR4 activation by SFAs (154, 155) and oxidative stress (331). Once activated, IKKβ 
phosphorylates and promotes the degradation of cytoplasmic IκBα, resulting in NF-κB release 
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and transcriptional activation of numerous NF-κB target genes, such as proinflammatory 
cytokines IL-6, TNFα and IL-1β (156-159). These cytokines, produced locally within cells, can 
act in an autocrine manner to activate signal transduction cascades that contribute to additional 
oxidative stress and inflammatory signaling to promote insulin resistance (149).  
Substitution of SFAs with MUFAs in the diet is beneficial in improving manifestations of 
metabolic diseases (183, 188, 332). The insulin sensitizing effects of dietary MUFAs are 
mediated, in part, by their ability to reduce inflammation, in both the periphery as well as the 
CNS (191, 333, 334). The MUFA oleate can reverse lipotoxic effects associated with palmitate 
exposure in several cell types in vitro (314, 316, 335). When injected directly into the CNS, 
MUFAs and PUFAs attenuate hypothalamic inflammation and promote weight loss (333). 
Abundant evidence indicates that MUFAs can act as signaling molecules and ligands of a number 
of molecular mediators including PPARs (197, 292). PPARs can reduce inflammation by 
repressing the activity of proinflammatory transcription factors, such as NF-κB and AP1 (289, 
290). Of the three known isoforms (α, δ/β, γ), PPARδ in particular is capable of regulating 
adaptive metabolic responses to changes in plasma FFA levels (336, 337). PPARδ is expressed at 
high levels throughout the CNS and is enriched in areas known to be involved in energy 
homeostasis, such as mediobasal hypothalamus (248, 252). Moreover, agonists of PPARδ have 
neuroprotective effects, reducing inflammatory responses to cytokines and oxidative stress in a 
variety of in vivo and in vitro neurological disease models (262, 263, 338).  
Evidence that PPARδ is activated by dietary MUFAs and has anti-inflammatory effects 
in peripheral tissues and the CNS, supported the hypothesis that dietary MUFAs activate PPARδ 
in hypothalamic neurons and that PPARδ is capable of opposing inflammation, cytokine 
expression and insulin resistance induced by excess SFAs in the diet. These experiments showed 
that chemical and dietary FFA ligands of PPARδ regulate target gene expression and oppose 
inflammation in mediobasal hypothalamus.  
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Results 
Differential effects of dietary monounsaturated and saturated fats on obesity 
To determine the relative contributions of total dietary fat intake and dietary FFA 
composition to the development of obesity, male Long Evans rats were fed LF control diet or one 
of two eucaloric HF diets (Table 3) for 10 weeks. Rats consuming HF-SFA diet gained 1.3-fold 
more body weight and 2.8-fold more fat mass than rats fed LF control diet ad lib (Figure 12A,B). 
Rats that consumed the HF diet enriched in MUFAs gained a third less body weight than those 
fed a diet high in SFA (Fig 12A,B, Table 5).  
 
Dietary fat composition is reflected in plasma and brain FFA 
To begin to test the hypothesis that dietary MUFAs are less obesogenic via effects on 
hypothalamic inflammation, plasma and cerebral cortex FFA levels as well as their composition  
 
Figure 12. Effects of dietary fat composition on diet-induce obesity. 
 
Long Evans rats were fed LF, HF-SFA or HF-MUFA diets for 10 weeks. A) Body weight and 
B) total amount body and fat mass gained over 10 weeks. Values represent group mean±SEM 
(n=5-6). Statistical significant is denoted as * (p<0.05 vs. LF) and/or # (p<0.05, HF-SFA vs. 
HF-MUFA). 
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Table 5 Metabolic parameters of Long Evans rats fed LF, HF-SFA or HF-MUFA diet 
for 10 weeks. 
Weight gain, fat mass gain and food intake represent cumulative total for weeks 1-10. Plasma 
hormone or metabolite concentrations correspond to 4-hour fasted values. Values represent 
group mean±SEM (n=5-6). Statistical significance is designated as 
a 
p<0.05 vs. LF and/or 
 b 
p<0.05 vs. HF; as measured by one-way ANOVA and post-hoc Tukey’s multiple comparison 
test.  
 
LF HF-SFA HF-MUFA 
body weight (g) 478.7±12.9 530.8±27.2
a
 489.7±19.7 
body weight gain (g) 159.1±11.1 200.2±18.5
a
 157.3±13.9
 b
 
fat mass (g) 64.8±8.1 113.0±19.6
a
 93.9±6.8 
fat mass gain (g) 32.2±5.5 86.3±17.7
a
 60.2±5.8 
adiposity (% fat) 13.4±1.4 20.5±2.6
a
 18.9±0.9 
food intake (kcal) 4,714±94 5,594±262
a
 5,281±98
a
 
plasma leptin (ng/mL) 7.4±1.0 20.3±4.7
a
 11.9±1.7 
plasma insulin (ng/mL) 2.1±0.4 3.4±0.6 2.3±0.1 
plasma glucose (mg/dL) 178.5±3.1 176.2±6.5 165.8±5.9 
plasma TG (µg/mL) 2,065±292 1,141±147 2,256±386
 b
 
plasma FFA (µg/mL) 74.5±14.6 67.4±5.3 80.1±13.8 
brain FFA (µg/mg) 0.50±0.06 0.56±0.06 0.51±0.04 
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were measured, to determine if PPAR ligands consumed in the diet could be detected in plasma 
and brain tissue, and thus act as ligands in the brain (Table 6). Although total levels of FFAs were 
similar between diet groups, the MUFA oleate (18:1ω9) was enriched in plasma (2.1-fold > LF) 
and to some degree in brains (1.3-fold > LF) of rats that consumed the HF-MUFA diet (Table 6). 
Consistent with both LF and HF-SFA diets having the same fat source (lard), but different total 
fat content, the species of individual FFAs were similar in plasma from rats consuming HF-SFA 
and LF diets. Palmitate (16:0) and oleate (18:1) each consisted of ~25% of FFAs in plasma 
(Table 6). Consumption of the HF-MUFA diet resulted in a doubling of oleate concentration, to 
~50% of total FFAs in plasma (Table 6). In addition to a small increase in the MUFA content in 
brain, HF-MUFA diet consumption increased the oleate to palmitate ratio from 0.6 with LF and 
0.7 with HF-SFA to 1 with HF-MUFA diet (Table 6). 
Table 6. Dietary fat composition is reflected in plasma and brain FFA 
 
Percent of total fatty acids in rats fed LF, HF-SFA or HF-MUFA diet for 10 weeks are 
listed. Values represent group mean±SEM (n=5-6). Statistical significant is denoted as 
a
 
(p<0.05 vs. LF) and/or 
b
 (p<0.05, HF-SFA vs. HF-MUFA). 
 
  
Plasma 
  
Brain 
 
Fatty acids LF HF-SFA HF-MUFA LF HF-SFA HF-MUFA 
C14:0 1.00±0.16 1.08±0.05 0.84±0.17 0.08±0.08 0.30±0.17 0.27±0.11 
C16:0 26.61±0.40 24.21±0.42
a
 18.79±0.50
a,b
 26.67±0.72 23.03±1.18 20.74±1.76
a
 
C18:0 11.84±1.02 13.74±0.42 7.65±0.60
a,b
 33.17±0.72 27.69±1.14
a
 28.02±0.66
a
 
Σ SFA 39.45±1.30 39.03±0.63 27.26±0.79a,b 59.92±1.25 51.01±1.04a 49.47±1.97a 
C16:1 5.03±0.30 1.98±0.14
a
 1.04±0.09
a
 0.09±0.09 0.09±0.09 0.10±0.10 
C18:1ω9 24.10±1.08 25.67±0.45 51.39±1.09a,b 15.50±0.72 17.00±0.57 19.85±0.63a 
Σ MUFA 34.30±1.35 30.11±0.42a 54.09±0.98a,b 18.78±0.54 21.01±0.37 23.65±0.92a 
C18:2 ω6 18.60±0.72 21.42±0.38a 14.56±0.37a,b 0.64±0.29 2.34±0.26a 1.67±0.16a,b 
C18:3 ω3 1.40±0.05 1.44±0.03 0.41±0.05 - - - 
C20:4 ω6 5.40±0.67 6.97±0.42 3.60±0.13b 18.04±0.60 19.98±1.05 20.69±1.12 
C22:6 ω3 1.03±0.12 1.04±0.09 0.49±0.12a,b 3.13±0.27 4.79±1.15 4.38±0.50 
Σ PUFA 26.25±1.00 30.85±0.45a 18.64±0.42a,b 21.29±0.85 27.83±1.15a 26.88±1.15a 
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Effects of dietary fat composition on hypothalamic stress and inflammation  
Protein markers of oxidative and ER stress in mediobasal hypothalamus were assessed by 
immunoblotting. After 10 weeks of consumption of HF-SFA diet, levels of an ER stress marker, 
phosphorylated PERK increased 1.5±0.1-fold relative to LF diet (Figure 13, p<0.05); 
additionally, an oxidative stress maker, phosphorylated p66shc increased 1.9±0.2-fold relative to 
LF diet (Figure 13, p<0.05). Levels of phosphorylated PERK and p66shc were similar between 
the HF-MUFA and LF-control groups, indicating that unlike HF-SFA diet, HF-MUFA diet for 10 
weeks did not activate these ER and oxidant stress pathways in the hypothalamus. 
 
 
 
Figure 13. Effects of dietary fat composition on hypothalamic oxidative stress and ER 
stress.  
 
Mediobasal hypothalamic total protein extracts from Long Evans rats fed LF, HF-SFA or HF-
MUFA for 10 weeks were subjected to Western blot analysis and probed with antibodies 
directed against the phosphorylated forms of PERK (p’PERK) and p66shc (p’p66shc). Levels 
of GAPDH were determined and used as a loading control. Inset shows representative 
Western blots. Densitometery of blots yielded relative intensity protein levels, which are 
represented as dietary group mean±SEM (n=5-6). Statistical significance is designated as 
a
 
(p<0.05 vs. LF) and/or 
b
 (p<0.05, HF-SFA vs. HF-MUFA), as measured by one-way ANOVA 
and post-hoc Tukey’s multiple comparison test. 
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Effects of dietary fat composition on biochemical markers of hypothalamic inflammation 
and PPARδ activation 
 
Rodent models of DIO exhibit increased hypothalamic cytokine expression after one 
week of HF diet exposure (313). To determine if dietary fat composition alters markers of 
hypothalamic inflammation, another cohort of rats were fed LF, HF-SFA or HF-MUFA diet for 7 
days, euthanized the animals and prepared mediobasal hypothalamic RNA. mRNA levels of the 
cytokine IL-6, a NF-κB target gene, as well as IκBα, an inhibitor of NF-κB (159, 339) were also 
determined. Relative to LF diet, HF-SFA diet consumption increased hypothalamic IL-6 gene 
expression 4.0±0.8-fold (Figure 14A, p<0.001), but did not significantly alter mRNA levels of 
IκBα (Figure 14A). In contrast, the HF-MUFA diet did not increase IL-6 mRNA levels relative to 
those of LF diet, but did increase IκBα mRNA levels 5.3±0.9-fold (Figure 14A, p<0.001). 
Induced expression of IκBα would be predicted to attenuate NF-κB signaling tone leading to 
reduced cytokine expression. Indeed, HF-MUFA diet led to 50% lower IL-6 mRNA expression 
relative to HF-SFA diet (Figure 14A).  
PPARδ is the most prevalent PPAR isoform in the CNS and is enriched in mediobasal 
hypothalamus (248). Hypothalamic PPARδ expression was determined following 7 days of LF, 
HF-SFA or HF-MUFA diet exposure. PPARδ mRNA was increased 1.9±0.2-fold only in animals 
fed the HF-MUFA diet (Fig. 14A, p<0.01). To determine if an increase in PPARδ mRNA 
expression resulted in an increase in function, the mRNA expression level of a known PPARδ 
target gene, uncoupling-protein 2 (UCP2) (340) was assessed. Indeed, the HF-MUFA diet 
increased hypothalamic UCP2 mRNA levels by 1.6±0.1-fold relative to LF control diet (Fig 14A, 
p<0.01). HF-SFA diet did not change UCP2 mRNA levels (Fig 14A), consistent with the 
possibility that HF-MUFA diet increased PPARδ ligands and thereby transcriptional activity; 
whereas, PPARδ ligands were not increased with HF-SFA diet consumption. To confirm that 
UCP2 is regulated by PPARδ ligand activation in the hypothalamus, an additional group of rats 
were implanted with a cannula to allow access to the third ventricle. Hypothalamic neurons were 
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exposed to an ICV bolus of a specific PPARδ agonist, GW0742 [36] (50 µg in 2 µL), and 
euthanized 24 hours later. Treatment with GW0742 significantly increased the mRNA level of 
UCP2 above vehicle treated by 1.7±0.2-fold (Fig 14B, p<0.05), confirming UCP2 in the 
hypothalamus as a specific PPARδ ligand activated target gene. 
 
Summary 
Diets rich in SFAs are associated with increased risk of obesity, diabetes and heart 
disease (30, 31, 119, 123). Replacing dietary SFAs with MUFAs and PUFAs has been shown to 
promote insulin sensitivity, weight loss and cardiovascular health (188, 189, 193, 332). To 
identify possible mechanisms involved in the differential effects of SFAs and MUFAs this 
investigation focused  on effects in the CNS; specifically hypothalamic neuronal inflammation 
and the possible role of PPARδ.  Long Evans rats were fed a LF control diet, HF diet enriched in 
 
Figure 14. Effects of dietary fat composition on hypothalamic inflammation and PPARδ 
activation.  
 
Hypothalamic mRNA levels in Long Evans rats A) after one week of feeding LF, HF-SFA or 
HF-MUFA diet or B) 24 hours after ICV treatment with either vehicle or GW0742. Target 
gene mRNA levels were normalized to endogenous RPL13A levels, and then expressed 
relative to that of A) LF diet for IL-6, IκBα, PPARδ, and UCP2 or B) vehicle for UCP2. 
Values represent group mean±SEM (n=5-6). Statistical significance is designated as A) 
a
 
(p<0.05 vs. LF) and/or 
b
 (p<0.05, HF-SFA vs. HF-MUFA), as measured by one-way ANOVA 
and post-hoc Tukey’s multiple comparison test or B) * (p<0.05), as measured by student’s t-
test. 
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the MUFA oleate and low in the SFA palmitate or HF diet with levels of palmitate, nearly 
equivalent to oleate. The results of these studies suggested that different types of dietary fats have 
differential effects on weight and adipose gain and on hypothalamic markers of ER and oxidant 
stress, inflammation, and expression of PPARδ as well as its target gene UCP2. These findings 
raise the possibility that PPARδ in the CNS has a role in the adaptive response to MUFA diet 
consumption and may be an interesting target to modulate cellular inflammation and stress 
induced by diets enriched in SFAs. 
To understand the influence of dietary fat composition on plasma and CNS FFAs, total 
and individual FFA levels in the FFA fraction of plasma and brains were determined in rats that 
consumed LF, HF-SFA or HF-MUFA diets for 10 weeks. Replacing the lard-based fat source of 
the HF diet with the oleate enriched safflower oil found in the MUFA diet led to a 24% increase 
in the relative amount of total MUFAs in plasma and reduced the relative amounts of SFAs by 
12%. The HF-MUFA diet also increased oleate levels to a small degree in brain tissue. In a 
similar study, Citra and colleagues reported a modest change in plasma and hypothalamic FFA 
composition after feeding mice two high-fat diets with different FFA compositions for 8 weeks 
(333).  
I also examined over the ten week experimental period several parameters involved in 
energy balance, such as body weight, fat mass gain and food intake. Both high-fat diets, HF-SFA 
and HF-MUFA, increased total caloric intake; yet only the high-fat lard based diet resulted in 
elevated body weight and increased fat mass gain. Given that dietary MUFAs, and not SFAs, are 
preferred substrates for fat oxidation (185, 341), energy expenditure may have increased with a 
MUFA diet based on the observation  that animals fed a HF-MUFA diet gained less total body 
weight from a caloric intake nearly equivalent to HF-SFA fed animals, indicating reduced feed 
efficiency with HF-MUFA diet. Compared to HF-SFA diet, consumption of HF-MUFA diet 
resulted in reduced activation of protein markers of hypothalamic inflammation, ER and 
oxidative stress, and prevented an elevation of plasma leptin and insulin levels, which suggests 
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that MUFAs contribute less toward leptin and insulin resistance. From a comparison of various 
metabolic parameters of LF, HF-SFA and HF-MUFA diet fed rats (Table 5), the oleate enriched 
HF-MUFA diet group showed greater protection from the poor prognostic indicators associated 
with the group fed a HF-SFA diet, perhaps due to less inflammation. 
In conclusion, in diets consisting of a high-fat content, dietary fatty acid composition is 
an important determinant in the physiological and molecular pathogenesis of DIO. In addition to 
providing calories to metabolism, some FFAs reduce cellular defense responses and promote 
lipotoxicity (SFA), whereas others are protective (MUFA). Therefore, activation of hypothalamic 
PPARδ by dietary and/or endogenous fatty acids may serve as a protective mechanism to prevent 
neuronal inflammation via upregulation of UCP2 or other target genes (IκBα) in key brain 
regions (hypothalamus) involved in energy homeostasis. CNS PPARδ gene expression is reduced 
in models of obesity and neurodegeneration (342, 343), raising the possibility that DIO is a state 
of acquired loss of PPARδ function in hypothalamic neurons. My study sheds important new light 
upon plausible mechanisms by which a changing dietary environment may multifactorially 
enhance susceptibility to obesity, and raise the possibility that neuronal PPARδ functions at a 
nexus involving gene transcription, inflammation, and sensitivity to leptin and insulin.  
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CHAPTER IV 
 
HYPOTHALAMIC NEURONAL PPARδ MEDIATES THE ANTI-INFLAMMATORY 
EFFECTS OF THE MONOUNSATURATED FATTY ACID OLEATE  
 
Introduction 
PPARδ is the most highly expressed PPAR isoform throughout the CNS and is enriched 
in areas known to be involved in energy homeostasis, such as mediobasal hypothalamus. While 
PPARs in general have been relatively understudied in the brain, PPARδ is perhaps the least 
understood. PPARδ regulates genes involved in cellular adaptive metabolic responses to FFAs 
(236, 237, 336, 344), and has been implicated in protective responses to oxidative stress and 
inflammation in both peripheral and CNS tissues (231, 260, 308, 345-353). A number of recent 
publications have centered on hypothalamic inflammation and its potential role in obesity 
pathogenesis (133, 137, 313). Additionally, diets enriched in PPAR ligands are beneficial in 
improving symptoms associated with metabolic diseases (186, 187, 354-358). However, since the 
hypothalamus contains heterogeneous cell types, it is difficult to assign these effects to its action 
in specific neurons as well as to identify in vivo, with traditional biochemical techniques, the role 
of individual molecules, such as a SFAs or MUFAs, to regulate PPARδ (359). 
Historical methods used to study hypothalamic neuronal populations, such as stereotactic 
injection, electrical stimulation or lesioning, can destroy, activate or disrupt these neurons and 
produce erroneous results. Also, many in vivo approaches do not address the molecular and 
cellular events or provide specific information of the mechanisms involved in gene regulation and 
cellular signaling within a given cell type. Additionally, these techniques do not allow direct 
testing of an agent on specific hypothalamic neurons. Although rodent genetic models have been 
used to study the effects of altered gene expression on signaling pathways, these models are time 
and labor intensive to create and study. Established cell lines, derived from hypothalamic tumors 
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or immortalized from primary cultures, provide a simpler model that lacks much of the 
complexity and challenges associated with in vivo study. Immortalized cell lines provide a 
homogeneous, clonal population of neuronal cells that can be maintained in a controlled 
environment for the study of changes in gene expression and/or cell signaling in response to 
specific test agents.  
For all these reasons, the differential effects of a MUFA, oleate, and that of a SFA, 
palmitate, were studied using a mouse clonal hypothalamic neuronal cell line, mHypoE-N42. 
This neuronal cell line allowed me to show that neuronal cells respond differently to MUFA and 
SFA FFAs and to explore more mechanistically the involvement of PPARδ in this differential 
response. These experiments revealed that both  chemical (GW0472) and common dietary 
(palmitate and oleate) FFA ligands of PPARδ regulate target gene expression and oppose 
inflammation. Conversely, inhibition of PPARδ with a chemical antagonist (GSK0660) in the 
presence of excess FFAs led to inflammation and insulin resistance. 
 
Results 
 
Regulation of PPARδ target gene expression by chemical agonists/antagonists and fatty 
acids in clonal hypothalamic neurons 
  
To investigate the role of PPARδ in the molecular events involved in the differential 
effects of dietary SFAs and MUFAs on hypothalamic neuronal inflammation,  in vitro 
experiments were perfomed using a clonal mouse hypothalamic neuronal cell line, mHypoE-N42 
(319). Two highly specific chemical modulators of PPARδ were used to manipulate PPARδ 
functional activity, which was monitored via changes in target gene (UCP2) expression. Changes 
in PPARδ and target gene mRNA levels were assessed by quantitative real-time PCR after a 24-
hour exposure to the PPARδ agonist GW0742 and/or the antagonist GSK0660 (214, 299). PPARδ 
gene expression was not altered by any of the treatments (Figure 15A). Activation of PPARδ with 
GW0742 increased UCP2 mRNA 4.1±0.2-fold above vehicle control levels (Figure 15A, 
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p<0.001). Conversely, treatment with a specific chemical antagonist of PPARδ, GSK0660, 
reduced UCP2 mRNA to 42±9% of control levels (Figure 15A, p<0.05) and inhibited GW0742 
induced expression of UCP2 to the level of GSK0660 alone (Figure 15A; GSK0660+GW0742 
0.42±0.17 to GW0742 4.1±0.2, p<0.001).  
I next utilized the mHypoE-N42 neuronal cell line to examine the effects of a common 
SFA and MUFA, palmitate (PA) and oleate (OA), respectively, on IL-6 and IκBα mRNA levels 
as well as that of PPARδ and its target gene, UCP2. Cells were exposed to low physiological 
concentrations of either oleate or palmitate bound to excess BSA (molar ratio of FFA to BSA 
0.7:1) for 24 hours. Palmitate exposure of mHypoE-N42 cells increased IL-6 mRNA 4.8±1.3-fold 
above vehicle-treated control levels (Figure 15B, p<0.05), while oleate had no effect. In these 
neuronal cells, IκBα mRNA levels were not altered by treatment with either fatty acid (Figure 
 
Figure 15. Effects of fatty acids and chemical ligands of PPARδ on gene expression in 
clonal hypothalamic neurons.  
 
A) PPARδ and UCP2 mRNA levels in cells treated for 24 hours with vehicle (0.05% DMSO, 
control), the PPARδ agonist GW0742 (1 nM) and/or the antagonist GSK0660 (1 μM). B) IL-
6, IκBα, PPARδ and UCP2 mRNA levels in cells exposed to vehicle (1% BSA, 0.05% 
DMSO; control), palmitate (PA, 100 μM) or oleate (OA, 100 μM) for 24 hours. Values 
represent group mean±SEM (n=4-5). Statistical significance is designated as 
a 
(p<0.05 vs. 
vehicle) and/or 
b 
(p<0.05 vs. PA), as measured by one-way ANOVA and post-hoc Tukey’s 
multiple comparison test.  
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15B). Compared to vehicle treatment, PPARδ gene expression was not altered by oleate treatment 
but trended (p<0.1) to be slightly reduced by palmitate (Figure 15B). Interestingly, relative to 
oleate treatment, PPARδ gene expression was significantly lower with palmitate treatment 
(Figure 15B; PA 0.57±0.11 to OA 1.2±0.2, p<0.05). Finally, oleate induced UCP2 mRNA 
3.3±0.5-fold above vehicle control levels (Fig 15B, p<0.001), while palmitate had no effect on 
UCP2 gene expression relative to the vehicle control (Figure 15B). 
Because cells are not physiologically exposed to a single fatty acid species (Table65), 
mHypoE-N42 cells were exposed to a mixture of fatty acids to determine if increasing levels of 
oleate would increase expression of UCP2, a PPARδ target gene in the presence of palmitate. 
When mHypoE-N42 cells were treated with either 100 or 250 µM palmitate, UCP2 mRNA levels 
were similar to control levels (Figure 16A). Compared to cells treated with 100 µM palmitate 
alone, the addition of 100 µM oleate increased UCP2 levels 2.9-fold (Figure 16A; 100 µM 
OA+100 µM PA 1.35±0.12 to 100 µM PA 0.47±0.02, p<0.01), while cells co-treated with 250 
µM oleate had 9.8-fold higher UCP2 mRNA levels relative to 100 µM palmitate treated cells 
(Figure 16A; 250 µM OA+100 µM PA 4.58±0.22 to 100 µM PA 0.47±0.02, p<0.001), suggesting 
a dose-dependent effect of oleate. Even in cells treated with a high dose (250 µM) of palmitate, 
the presence of 100 µM oleate increased UCP2 mRNA levels 2.8-fold (Fig 16A; 100 µM 
OA+250 µM PA 1.57±0.08 to 250 µM PA 0.56±0.34, p<0.05), while 250 µM oleate increased 
UCP2 mRNA levels by 5.2-fold (Fig 16A; 250 µM OA+250 µM PA 2.90±0.46 to 250 µM PA 
0.56±0.34, p<0.001).  
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The selective chemical PPARδ inhibitor, GSK0660, was used to determine if PPARδ 
activation is required for the effect of 100 µM oleate to increase UCP2 mRNA levels in the 
presence of 250 µM palmitate (Figure 16B). Treatment with oleate in combination with palmitate 
increased UCP2 mRNA levels by 3.1±0.6-fold compared to vehicle control treatment (Figure 
16B; p<0.01), whereas inhibition of PPARδ with the chemical antagonist GSK0660 reduced 
UCP2 mRNA levels to 16.1±0.2% of the levels of combined oleate and palmitate FFA treatment 
alone (Figure 16B; p<0.001). These data suggest that oleate increases PPARδ functional activity 
to maintain or even induce target gene expression, as seen with UCP2. 
 
 
 
 
 
Figure 16. PPARδ activation is required for oleate induced UCP2 mRNA expression in 
clonal hypothalamic neurons.  
 
A) UCP2 mRNA levels in mHypoE-N42 cells treated with palmitate alone (PA) or co-treated 
with oleate (OA+PA) with constant BSA (100 µM) at the indicated concentrations for 24 
hours and expressed relative to vehicle (BSA) treated cells (control). B) UCP2 mRNA levels 
after co-treatment with OA+PA in the presence or absence of GSK0660 (1 μM) or vehicle 
(0.05% DMSO; control). Values represent group mean±SEM (n=4-5). Statistical significance 
is designated as 
a 
(p<0.05 vs. vehicle) and/or 
b 
(p<0.05 vs. PA), as measured by one-way 
ANOVA and post-hoc Tukey’s multiple comparison test. 
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PPARδ activation by GW0742 attenuates palmitate induced inflammation in clonal 
hypothalamic neurons  
 
In the hypothalamic mHypoE-N42 cell line, IL-6 and IκBα mRNA levels were measured as 
markers of pro-inflammatory and anti-inflammatory signaling, respectively (339, 360) in order to  
determine if ligand-specific activation of PPARδ attenuates palmitate induced inflammation in 
neurons. In cells treated with palmitate, IL-6 mRNA levels increased 4.8±1.3-fold compared to 
vehicle-treated cells (Figure 17, p<0.05), whereas there was no change in IκBα mRNA levels. 
Ligand-specific activation of PPARδ with the chemical agonist GW0742 (1 μM) almost 
completely attenuated (62% reduction) the palmitate-induced IL-6 mRNA levels (Figure 17; 
PA+GW0742 1.8±0.2 to PA 4.8±1.3, p<0.05). GW0742 treatment also resulted in a 1.7-fold 
increase in IκBα mRNA levels in the presence of palmitate relative to palmitate alone (Figure 17; 
 
Figure 17. PPARδ activation by GW0742 prevents palmitate induced inflammation in 
clonal hypothalamic neurons. 
 
mHypoE-N42 cells were incubated for 24 hours with vehicle (1% BSA, 0.05% DMSO; 
control) or palmitate (PA, 100 μM) in the presence or absence of GW0742 (1 μM). Changes 
in IL-6, IκBα, PPARδ and UCP2 mRNA levels were assessed by quantitative real-time PCR 
and mRNA levels are expressed relative to that of control. Values represent group 
mean±SEM (n=4-5). Statistical significance is designated as 
a 
(p<0.05 vs. vehicle) and/or 
b 
(p<0.05 vs.PA), as measured by one-way ANOVA and post-hoc Tukey’s multiple 
comparison test.  
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PA+GW0742 1.5±0.1 to PA 0.92±0.14, p<0.05). PPARδ gene expression was not altered by any 
of the treatments (Figure 17). Similar to the effect of oleate, treatment of palmitate along with the 
PPARδ agonist GW0742 increased UCP2 mRNA 3.7-fold above the level seen with palmitate 
alone (Figure 17; PA+GW074, 3.7±0.4 to PA 0.97±0.16, p<0.001). These data suggest that 
PPARδ activation has anti-inflammatory effects in the mHypoE-N42 hypothalamic neuronal cell 
line. Ligand activated PPARδ mediates this effect by suppressing inflammatory cytokine gene 
expression, while promoting the expression of an "anti-inflammatory” NF-κB regulatory gene, 
IκBα. 
 
Inhibition of PPARδ with GSK0660 leads to inflammation and insulin resistance in clonal 
hypothalamic neurons exposed to excess fatty acids 
 
The  mHypoE-N42 cell line was next used to determine whether PPARδ function was 
necessary to maintain the beneficial effects of the MUFA, oleate, in the presence of the SFA, 
palmitate. Cells were treated with a mixture of oleate (100 µM) and palmitate (250 µM). BSA 
was held at 100 µM to yield an FFA to BSA ratio of 3.5:1 to examine how excess FFAs and loss 
of PPARδ function might impact inflammation and insulin signaling in this hypothalamic 
neuronal cell line. Inhibition of PPARδ with GSK0660 (1 µM) in the presence of oleate and 
palmitate led to a loss of cytoplasmic IκBα protein levels to 46±8% of the levels of combined 
oleate and palmitate treatment alone (Figure 18A, p<0.01). In the context of reduced IκBα and 
presumed NF-κB activation, treatment with GSK0660 increased IL-6 gene expression by 1.9±0.1-
fold (Figure 18B, p<0.05). Likewise, expression of a second NF-κB regulated proinflammatory 
cytokine gene, IL-1β, was also increased 1.8±0.4-fold (Figure 18B, p<0.05).  
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Figure 18. Inhibition of PPARδ with GSK0660 leads to IκBα degradation, 
inflammation, and insulin resistance in clonal hypothalamic neurons exposed to fatty 
acids.  
 
mHypoE-N42 cells were incubated for 24 hours with a mixture of fatty acids conjugated 
to BSA (BSA, 100 µM; oleate, 100 µM; palmitate, 250 µM; final FFA concentration 350 
µM) in the presence or absence of GSK0660 (1μM, 0.05% DMSO). A) Total protein 
extracts were subjected to Western blot analysis and immunological detection of 
cytoplasmic IκBα protein was quantified by densitometry. Heat shock cognate protein 70 
(HSC70) was used as a loading control and treatment levels are expressed relative to 
those in the absence of GSK0660. Insert of A shows a representative Western blot. B) 
Changes in mRNA levels of the cytokines, IL-6 and IL-1β, with GSK0660 treatment were 
assessed by quantitative real-time PCR. Treatment levels are expressed relative to those in 
the absence of GSK0660. C) Insulin induced Akt phosphorylation was assessed in total 
protein extracts prepared from mHypoE-N42 cells stimulated with insulin (10 nM) for 5 
minutes by immunological detection of phosphorylated and total Akt proteins using the 
indicated antibodies and expressed relative to total Akt levels. Treatment levels are 
expressed relative to those in the absence of insulin and GSK0660. Values represent 
group mean±SEM (n=4). Statistical significance is designated as 
* (p<0.05) by student’s t-
test; or in panel C, when measured by one-way ANOVA and post-hoc Tukey’s multiple 
comparison test,
 * 
(p<0.05 vs. no insulin treatment) or 
# 
(p<0.05 vs. insulin treated, no 
GSK0660 treatment). 
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Rodent models of DIO are usually associated with increased inflammatory signaling 
accompanied with insulin resistance in mediobasal hypothalamic neuronal populations (133, 
137). A chemical inhibitor of PPARδ, GSK0660 was utilized to determine if loss of PPARδ 
function also promotes insulin resistance in the hypothalamic neuronal mHypoE-N42 cell line. In 
cells treated with insulin in the presence of oleate and palmitate compared to this FFA mixture 
alone, insulin stimulation (10 nM, 5 minutes) increased phosphorylation of Akt at serine-473 by 
1.5±0.1-fold (Figure 18C, p<0.01). Inhibition of PPARδ with GSK0660 did not alter total levels 
of Akt, but prevented insulin-induced phosphorylation of Akt (Figure 18C; insulin with 
OA+PA+GSK0660 1.11±0.01 to insulin with OA+PA 1.47±0.08, p<0.05). Collectively, these 
results suggest that PPARδ may sense and be activated by dietary MFUAs, like oleate, to oppose 
stress and inflammatory signaling, preventing hypothalamic neuronal insulin resistance. 
 
Summary 
High-fat diets are associated with inflammatory signaling in neuronal targets of insulin 
and leptin (133, 137), which may play a causative role in the development of central hormonal 
resistance and the pathogenesis of obesity. Conversely, the protective effects of omega-3 
polyunsaturated fats on insulin sensitivity and inflammation have been appreciated for some time 
(361, 362). Diets rich in the MUFA oleate improve insulin sensitivity (187, 188, 191, 192, 332, 
363) and promote weight loss (186, 341, 354). This led to the hypothesis that MUFAs activate 
PPARδ in hypothalamic neurons resulting in increased expression of target genes that oppose 
inflammation, cytokine expression and insulin resistance induced by excess SFAs in the diet. To 
identify possible mechanisms involved in the differential metabolic effects of SFAs and MUFAs, 
the investigation was focused specifically on hypothalamic neuronal inflammation and insulin 
resistance, using the hypothalamic neuronal cell line, mHypoE-N42.  
MUFAs and PUFAs activate PPARδ with µM affinity in vitro (364). However, cells are 
exposed to a heterogeneous mixture of both saturated and unsaturated fatty acids in vivo. 
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Therefore, the cell culture system provided an opportunity to test the effects of individual fatty 
acids on gene expression and inflammation at biologically relevant concentrations. Treatment of 
cells with the MUFA oleate increased UCP2 mRNA levels, while treatment with the SFA 
palmitate had no effect on UCP2 gene expression. The ability of oleate to restore and induce 
UCP2 gene expression in the presence of palmitate was dependent on both the concentration of 
each FFA as well as the ratio of MUFA:SFA with the largest response occurring at a MUFA to 
SFA ratio of 2.5:1, which closely matched plasma levels of oleate and palmitate after 10 weeks of 
HF-MUFA diet feeding (Table 6). Treatment with the PPARδ antagonist GSK0660 abolished 
UCP2 expression induced by co-treatment with oleate and palmitate, indicating a specific role for 
PPARδ in oleate induced UCP2 expression in hypothalamic neurons. Oleate induced UCP2 
expression was also shown to be dependent upon PPARδ in INS-1E cells, an insulin secreting cell 
line [61]. Additionally, mutant mice expressing a mutated form of PPARδ that lacks the ligand-
binding domain, a region necessary for fatty acid activation of gene transcription, cannot up-
regulate UCP2 in response to fasting, and are more susceptible to neuronal oxidative stress and 
ischemic injury [65]. GSK0660 is a highly specific PPARδ antagonist and only cross-reacts with 
other PPAR isoforms at an extremely high concentration (>10 µM), which further supports a 
neuronal PPARδ specific mechanism to increase UCP2 mRNA [53].  
Dietary SFAs induce hypothalamic inflammation in rodents, but there is little evidence to 
support neurons and not glial cells as the primary source of increased inflammatory signaling and 
cytokine expression (313, 329). Similar to the effect after one week of SFA-rich HF diet feeding, 
palmitate increased IL-6 mRNA levels in mHypoE-N42 hypothalamic neuronal cells. Activation 
of PPARδ with GW0742 attenuated the palmitate-induced gene expression of IL-6 as well as 
increased IκBα mRNA levels 1.7-fold above palmitate treatment alone. These findings are 
consistent with extensive evidence that PPARδ activation is protective against SFA induced 
lipotoxicity (Coll, Alvarez-Guardia et al. 2010; Jiang, Wan et al. 2010; Wan, Jiang et al. 2010; 
Wang, Liu et al. 2010; Alvarez-Guardia, Palomer et al. 2011. IκBα sequesters NF-κB in the 
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cytoplasm, preventing its translocation to the nucleus. The IκBα promoter contains several 
confirmed PPREs and IκBα mRNA expression and protein levels are increased in response to 
treatment with PPAR chemical agonists (339). PPARs are known to prevent inflammation 
through ligand dependent trans-repression of the p50/p65 subunits of NF-κB, and with AP1, 
effectively blocks association of these transcription factors with their DNA response elements 
(231, 308). Although my studies do not differentiate by which mechanism PPARδ activation 
reduces inflammation, they clearly implicate the involvement of PPARδ.  
Persistent exposure to elevated FFA levels during obesity induces lipotoxicity and insulin 
resistance (326, 365). The clonal neuronal cells were next treated with a mixture of oleate and 
palmitate to better recapitulate physiological FFAs, since neurons are never exposed to a single 
FFA species. This experiment tested the hypothesis that PPARδ mediates the action of the MUFA 
oleate in mHypoE-N42 hypothalamic neuronal cells, by protecting these cells from the effects of 
SFA-induced lipotoxicity and thereby maintaining insulin responsiveness. Insulin signaling was 
maintained despite the presence of high levels of FFAs in the culture media as long as the MUFA 
oleate was present with the SFA palmitate. Specific inhibition of PPARδ with GSK0660 in the 
presence of oleate and palmitate prevented insulin induced phosphorylation of Akt. Inhibition of 
PPARδ action with GSK0660 in the presence of oleate and palmitate also led to a 50% reduction 
in IκBα protein and increased mRNA levels of the proinflammatory cytokines IL-6 and IL-1β. 
Loss of PPARδ function leads to biochemical events that resemble those occurring in rodent 
models of DIO, which exhibit reduced hypothalamic levels of cytoplasmic IκBα, increased 
cytokine expression and insulin resistance (133, 137, 313). PPARδ gene expression is reduced in 
several disease models, including diabetes, aging, obesity and inflammatory disease (342, 343); 
therefore, these findings raise the possibility that DIO is a state of acquired loss of PPARδ 
function.  
In conclusion, in diets consisting of a high-fat content, dietary fatty acid composition is 
an important determinate in the physiological and molecular pathogenesis of DIO. In addition to 
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providing calories to metabolism, some FFAs reduce cellular defense responses and promote 
lipotoxicity (SFA), whereas others are protective (MUFA). My investigation and findings support 
a role for PPARδ as a diet responsive fatty acid “sensor” that may mediate the protective effects 
of unsaturated fats from DIO associated inflammation and insulin resistance in hypothalamic 
neurons 
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CHAPTER V 
 
CNS DELETION OF PPARδ LEADS TO INCREASED SUCEPTABILITY TO DIET-
INDUCED OBESITY 
 
Introduction 
All three PPAR isoforms are expressed to different degrees in the CNS (239). Recent 
evidence suggests that CNS activation of PPARα and/or PPARγ may contribute to weight gain 
and obesity (242, 366). Deletion of PPARγ in neurons (366), or chemical inhibition of PPARγ in 
the hypothalamus (242), protects against the development of DIO . Activation of this receptor 
with HF feeding or a chemical agonist increases weight gain (242), raising the possibility that 
HFD consumption activates neuronal PPARγ, which may be a pathogenic mechanism associated 
with obesity. PPARδ, the most highly expressed isoform throughout the CNS, is enriched in areas 
known to be involved in energy homeostasis, such as mediobasal hypothalamus (239, 248, 252). 
Accumulating evidence supports a role for CNS PPARδ activation in preventing oxidative stress 
and inflammation in several neurodegenerative models (263, 338). Although limited, these 
reports support a key role for PPARs in central energy homeostasis regulation.  
Evidence from various rodent models suggests that hypothalamic lipid accumulation and 
low-grade inflammation are associated with obesity (133, 313). Agonists of PPARδ oppose HF 
diet induced inflammation and insulin resistance in peripheral tissues, in part through 
transcriptional activation of target genes whose encoded proteins are involved in mitochondrial 
fatty acid oxidation, proliferation and uncoupling (231, 234, 236, 238, 308). In the CNS, PPARδ 
has been implicated in reducing neuronal inflammation via down regulation of NF-κB signaling 
as well as neuroprotection from inflammation and excitotoxicity (reviewed in (323). Despite the 
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fact that this potent transcriptional regulator is highly expressed in the CNS, little is known of the 
transcriptional targets regulated by PPARδ in the brain. 
UCP2 is a validated target gene of PPARδ and global PPARδ KO mice fail to express 
UCP2 in the CNS in response to fasting. Extensive data implicate UCP2 in neuroprotection, 
reduction of CNS oxidative stress and neuroinflammation. Genetic deletion of UCP2 in mice also 
results in chronic basal NF-κB activation (367), which suggests an important role protecting 
against basal metabolic stress. Therefore, this gene can serve as a marker of PPARδ activation. 
In a hypothalamic neuronal cell line, PPARδ was found to regulate UCP2 gene 
expression in response to a chemical agonist and FFAs commonly encountered in the diet. 
Conversely, exposure to the antagonist GSK0660 reduced basal expression of UCP2 and blocked 
oleate induced UCP2 expression. This suggested that activation of hypothalamic PPARδ by 
dietary FFAs may serve as a protective mechanism to prevent neuronal inflammation via 
upregulation of UCP2 or other target genes expressed in this brain region. Inhibition of PPARδ 
with the chemical antagonist GSK0660, led to biochemical events that resembled those occurring 
in rodent models of DIO, including reduced hypothalamic levels of cytoplasmic IκBα, increased 
cytokine expression and insulin resistance (137, 313). PPARδ gene expression is reduced in 
several disease models, including diabetes, aging, obesity and inflammatory disease [74-77]; 
therefore, my findings raise the possibility that DIO is a state of acquired loss of PPARδ function. 
 
Results 
CNS PPARδ knockdown and brain morphology 
PPARδ was deleted from neurons using cre-lox technology (368). Mice expressing Cre 
recombinase under the control of the rat Nestin promoter (Nestin Cre
+/+
) (369) were crossed with 
mice engineered with Lox-P recognition sites flanking exon 4 of the PPARδ gene (f/f; PPARδf/f) 
(Figure 11) to obtain double transgenic, heterozygous (Het; PPARδf/wt Nestin Cre+/-) mice which 
were crossed to obtain CNS PPARδ knockout (KO; PPARδf/f Nestin Cre+) mice.  
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Figure 19. Validation of CNS PPARδ lox-P knock-out mouse model.  
A) UV detected PCR products, stained with EtBr, used to illustrate genotyping are shown. 
Genotypes were confirmed through PCR of hypothalamic DNA using primers for wild type 
(wt) and floxed (f/f) alleles of PPARδ as well as Nes promoter-Cre recombinase transgene 
(+). Double heterozygous crosses yielded 6 genotypes (Lane 1, PPARδwt/wtNestin-Cre-; lane 
2, PPARδwt/wtNestin-cre+; lane 3, PPARδfl/wt Nestin-cre-; lane 4 PPARδfl/wtNestin-cre+ (Het); 
lane 5, PPARδfl/fl Nestin-cre- and lane 6, PPARδfl/fl Nestin-cre+ (KO)). B) Representative 
Western blot of PPARδ levels in total cellular protein extracts from mediobasal hypothalamus 
of f/f and KO mice. β-tubulin was used as a loading control. C) Quantification of tissue 
PPARδ mRNA expression in f/f and KO mice (muscle, liver, white adipose tissue (WAT), 
brown adipose tissue (BAT), cerebral cortex and hypothalamus). PPARδ mRNA levels were 
measured by RT-PCR and normalized to endogenous levels of the housekeeping gene 
RPL13A (n=4-8). Values represent the mean ± SEM of each genotype group. Statistical 
significance is designated as *(p<0.05 vs. f/f control group), as determined by two tailed 
student’s t test.    
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Global deletion of exon 4 of the PPARδ gene leads to embryonic lethality in mice (302).  The 
effect of CNS PPARδ deletion on embryonic viability and neonate survivability was assessed 
through a Chi square analysis of genotypes with a comparison to expected Mendalian ratios of 
offspring. This analysis of genotypes indicated that neuronal ablation of PPARδ was not lethal 
(p<0.001). PPARδ Het and KO mice were fertile and had no apparent developmental 
abnormalities compared to their floxed (PPARδf/f) littermate control mice.   
Genotypes were confirmed through PCR of hypothalamic DNA using primers for wild 
type and floxed alleles of PPARδ as well as the Nestin-Cre transgene. The PCR products were 
visualized by UV detection of DNA bands stained with EtBr (Figure 19A). Mice with the wild 
type allele for PPARδ were identified by a single band at 359 bp, mice homozygous for the 
floxed allele were identified by a single band at 400 bp and heterozygotes by the presence of both 
the wild type and floxed alleles (Figure 19A, top panel). A single 100 bp band indicated the 
presence of the Nestin-Cre transgene (Figure 19A, bottom panel).  Hypothalamic PPARδ protein 
levels, as determined by the presence of an immuoreactive species, were qualitatively reduced in 
KO compared to control mice, as assessed through Western blot analysis of total hypothalamic 
protein extracts (Figure 19B). 
PPARδ is ubiquitously expressed and is an important regulator of lipid metabolism in a 
number of peripheral tissues, including muscle (223, 227-231), liver (336, 370-374), brown 
adipose tissue (BAT) (375) and white adipose tissue (WAT)(235). Quantitative RT-PCR of 
PPARδ mRNA confirmed that peripheral levels were not different between KO and control mice 
(Figure 19C). Neuronal deletion led to a 74±6% reduction in cortex and an 88±1% reduction in 
hypothalamus of PPARδ mRNA of KO mice relative to f/f control mice (Figure 19C, p<0.001).  
Global genetic deletion of the LBD of PPARδ leads to reduced brain size and  
myelination defects (254). Histological analysis was performed to determine if  the CNS is 
grossly altered by neuronal deletion of the DBD of PPARδ. Nissl stained coronal sections 
(Figure. 20) at the level 
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of the hippocampus (top panel) and hypothalamus (bottom panel) revealed no obvious differences 
between KO mice and control (f/f) or unfloxed negative controls (Nes-Cre, Figure 20), indicating 
no malformations in the structure of these or any other forebrain nuclei. Additionally, brain 
weight was not different between f/f and KO mice (f/f, 0.46±0.01 g vs. KO, 0.47±0.01 g, p=0.82), 
consistent with normal CNS morphology. PPARδ KO mice were fertile and had no apparent 
developmental abnormalities compared to f/f control. I proceeded to use this animal model to 
study the effects of loss of neuronal PPARδ function on energy homeostasis.  
 
Body weight and composition of CNS PPARδ KO mice fed chow diet 
I hypothesized that PPARδ regulates gene expression in response to endogenous lipids, 
and with its deletion, an obese phenotype on a chow diet would ensue.  
 
Figure 20. Brain morphology in CNS PPARδ KO mice.  
 
Photomicrographs of Nissl staining of brains from PPARδ KO and control, PPARδf/f (f/f) and 
Nestin-Cre, mice are illustrated. Representative sections shown at the level of the 
hippocampus (top) and hypothalamus (bottom). Scale bar = 500 μm. 
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Body weight and body composition were assessed in 5-week-old f/f and KO mice fed a chow diet 
to determine if genetic loss of neuronal PPARδ alters the basal phenotype of mice. Interestingly, 
body weight (BW) was reduced by 13±1% in KO mice (Figure 21A, p<0.001), a difference that 
was largely due to a 12±1% reduction in lean body mass (Figure 21A, p<0.001). Despite lower 
total BW, fat mass was slightly but significantly increased by 16±1% (Figure 21A, p<0.05). 
Adiposity, which indicates the percentage body fat (fat mass/BW x 100), was increased by 
138±1% in KO mice (Figure 21A, p<0.01). Elevated adiposity was due to increased fat storage in 
adipose, as seen by a near doubling of epididymal adipose tissue in 12-week-old PPARδ KO mice 
(Figure 21B) and higher circulating basal leptin levels (Figure 21C). 
 
CNS PPARδ deletion leads to altered body composition and leptin insensitivity  
Leptin acts as an adiposity negative feedback signal, controlling fat mass (34, 376) 
through the coordinated regulation of food intake and energy expenditure. Resistance to the  
 
Figure 21. Effects of CNS PPARδ deletion on body weight and adiposity.  
 
A) Total body weight (total), lean and fat mass.(body composition) and percentage fat 
(adiposity) was measured in 5-week-old, chow-fed f/f and KO mice. B) Epigonadal fat pad 
mass and C) plasma leptin levels in aged-matched, chow-fed f/f and KO mice are shown. 
Values represent the mean ± SEM. Statistical significance is denoted by * (p<0.05, vs. f/f 
controls), as determine by two-tailed student’s t test.  
 
 
78 
 
 
 
behavioral and biochemical effects of leptin is a hallmark of obesity (136). Leptin treatment  
(5mg/kg BW, IP) reduced 24-hour caloric intake (kcal/g BW) by 24% in f/f mice (Figure 22A, 
p<0.05) compared to vehicle, but failed to reduce food intake in KO mice (Figure 22A). STAT3 
is a direct molecular target of leptin receptor activation (44) and its phosphorylation state can be 
used as a biochemical marker of leptin sensitivity (95). Leptin treatment (5mg/kg BW, IP) 
increased phosphorylation of STAT3 (Y705) by 4.6±0.5-fold in hypothalami of f/f mice, while 
KO mice exhibited a significantly reduced response to leptin treatment, which increased 
phosphorylation by only 3.7±0.3-fold in the KO group (Figure 22B, p<0.05).  
 
 
 
 
 
Figure 22. Effect of CNS PPARδ deletion on hypothalamic leptin sensitivity.  
 
A) Food intake in chow-fed f/f and KO mice were measured after receiving a bolus injection 
of leptin (5 mg/kg BW, IP) or vehicle (saline) at the onset of the dark period. Mice were 
housed individually and food intake was measured over 24 hours (n=10-12). Values represent 
the mean ± SEM. (B) Hypothalamic total protein extracts from f/f and KO mice treated with 
leptin (5 mg/kg BW, IP) or vehicle for 30 minutes were used for Western blot analysis of 
STAT3 phosphorylation (Y705). Total STAT3 levels were determined and used as a loading 
control. Densitometery of blots yielded relative intensity levels, which are expressed as an 
activation index (pSTAT3/total STAT3) and represented as the group mean ±SEM (n=4-6) 
relative to the f/f vehicle group. Statistical significance is denoted by * (p<0.05, leptin (black 
bars) vs. vehicle (white bars) treated groups within each mouse genotype) and/or # (p<0.05, 
KO vs. f/f mice treated with leptin), as determined by two-way ANOVA and Bonferroni post 
test.  
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Altered neuropeptide gene expression and compensatory refeeding after prolonged fasting 
in CNS PPARδ KO mice. 
 
NPY is a powerful orexigenic neuropeptide and activator of food intake that is potently 
induced by fasting and in the absence of leptin signaling (83, 84, 86, 377). In this situation, 
simultaneous inhibition of POMC neurons (and down regulation of anorexogenic POMC gene 
expression) facilitates subsequent hyperphagia and weight regain (89). Consistent with leptin 
resistance in KO mice (Figure 22), hypothalamic NPY mRNA levels were elevated (Figure 23A) 
 
 
Figure 23. Effects of CNS PPARδ deletion on neuropeptide expression and the refeeding 
response after a prolonged fast.  
 
A-C) Fasting induced changes in NPY (A), POMC (B) and UCP2 (C) hypothalamic mRNA 
levels of f/f and KO mice fed chow diet ad libitum (fed) or fasted for 24 hours (fast). Target 
gene mRNA levels were normalized to RPL13A mRNA levels and shown as the group mean ± 
SEM, expressed relative to the fed, f/f control. D) Food intake (chow diet) during a 24-hour 
refeeding period was measured after fasting in a separate cohort of individually housed mice 
(n=6-7). Graph shows food intake normalized to basal, pre-fast lean mass (kcal/g lean mass). 
E) Percent changes in body weight after fasting, refeeding for 24 hours or 1 week. In A-C, 
statistical significance is designated by 
a 
(p<0.05, f/f vs. KO, same treatment) and/or 
 b 
(p<0.05, 
fed vs. fast, same genotype), as determined by two-way ANOVA and Bonferroni post test, or 
in D and E by * (p<0.05, vs.f/f), when determined by two-tailed student’s t test. 
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and POMC gene expression was reduced in the fed state (Figure 23B). Fasting elicited the 
appropriate neuropeptide gene expression pattern, increasing NPY mRNA levels by 1.75-fold 
(Figure 23C) and decreasing POMC gene expression by half (Figure 23D), in hypothalami of f/f 
mice. Fasting in KO mice, paradoxically, decreased NPY expression (Figure 23A) but did not 
further reduce POMC gene expression relative to fed KO mice (Figure 23B).  
UCP2 mRNA levels are induced by fasting in hypothalamic NPY and POMC neurons, 
where it has been implicated in hypothalamic nutrient sensing, hormone signaling, neuronal firing 
and neuropeptide gene expression (induction of NPY and repression of POMC) (116). My 
previous experiments (Chapter 3, Figure 16) confirmed that UCP2 is a target gene of PPARδ in a 
clonal hypothalamic neuronal cell line. KO mice should therefore exhibit an abnormal 
transcriptional response to physiological elevations in lipid, that could be detected at the level of 
UCP2 gene expression. Consistent with this, UCP2 gene expression was increased 1.6-fold by 
fasting in hypothalami of f/f mice but was unchanged in fasted KO mice (Figure 23C), given the 
UCP2 requirement for NPY induction (116) and that UCP2 is a gene target of PPARδ, this 
suggests a potential molecular mechanism for disruption of neuropeptide gene expression in CNS 
PPARδ KO mice.  
To understand the functional implications of altered neuropeptide expression in KO mice,  
food intake was determined in a second group of individually housed mice following a 24 hour 
fast. Consistent with blunted fasting induced UCP2 and NPY expression, KO mice consumed 
significantly fewer calories (normalized to lean mass, kcal/g lean mass) after fasting (Figure 
23D), resulting in attenuated weight regain after 24 hours of refeeding (Figure 23E). Interestingly, 
KO mice gained significantly more weight than f/f mice in the 8 days following the fasting 
challenge (Figure 23E), consistent with the reduced POMC gene expression in fed KO mice, 
suggesting that stress-induced weight gain may be exaggerated in the long term. Together with 
impaired leptin sensitivity, these data raise the possibility that loss of PPARδ function in neurons 
impairs both anorexogenic and orexigenic tone.  
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Figure 24. Effects of CNS PPARδ deletion on susceptibility to diet induced obesity.  
 
Growth curves of f/f and KO mice fed LF or HF diet for 33 weeks (age 5-38 weeks) are 
shown for body weight (A) and (B) fat mass, measured at the indicated ages. Total weight 
gain over the experimental period for body weight (C), lean (D), and fat mass (E) is shown 
for f/f and KO mice. Cumulative food intake as kcal (F) and feed efficiency of f/f and KO 
mice fed LF (G) or HF (H) diet (weight gained (either BW, fat or lean mass)/cumulative 
kcal). Values represent the mean±SEM. Statistical significance in A-B is denoted by * (LF f/f 
vs. LF KO) and # (HF f/f vs. HF KO) or in C-E as 
a
 (p < 0.05, f/f vs. KO, same diet) and/or 
b
 
(p< 0.05. LF vs. HF, same genotype), when determined by one-way ANOVA and Bonferroni 
post test, or in G and H, by * (p<0.05 vs. f/f controls), when determined by two-tailed 
student’s t test. 
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CNS PPARδ deletion leads to increased susceptibility to diet-induced obesity  
Given the known role of PPARδ in the regulation of genes that reduce oxidative stress 
and promote lipid oxidation (223) and its recognized anti-inflammatory effects in the CNS (323), 
Based on this evidence, PPARδ could act as an important molecular determinant of susceptibility 
to environmentally induced obesity. To test this, at 5 weeks of age, mice were placed on a diet 
with HF content (45% kcal as fat) or a micronutrient matched control diet with LF content (10% 
kcal as fat).  
Although smaller at weaning, KO mice have normal growth and gain a similar amount of 
weight as f/f mice over 33 weeks of LF diet feeding (Figure 24A, C). Exposure to HF diet led to 
significant weight gain in both genotypes. However, KO mice were more susceptible to DIO, 
becoming significantly heavier than HF fed f/f control mice after 33 weeks (Figure 24A). At the 
end of the 33-week experimental period, HF fed KO mice had gained 16% (~5g, Figure 24C) 
more body weight and were 6% heavier than f/f mice fed the same HF diet (Figure 24A), 
revealing a role for neuronal PPARδ expression in the determination of body weight gain and 
DIO susceptibility. 
Differences in body composition can have profound effects on the metabolic implications 
of weight gain. On LF diet, KO mice have reduced lean mass gain (Figure 24D), whereas HF 
feeding lead to identical lean mass gain. At baseline, KO mice have slightly more fat mass 
(Figure 24B), which is maintained over the course of 33 weeks of LF diet feeding (Figure 24E). 
The effect of HF diet consumption to induce obesity was augmented in KO mice, which had 6 
grams or 33% more fat mass than f/f control fed HF diet (Figure 24B, EF). These data show that 
increased body weight gain in KO mice on HF diet was due to a profound accumulation of fat 
mass and reveals a significant interaction between CNS PPARδ function and dietary fat exposure. 
Absolute food intake was reduced in KO mice fed LF diet, whereas no differences in 
cumulative (33 weeks) food intake were observed between the genotypes on HF diet (Figure 
24F). Feed efficiency (calories consumed to gain 1 gram of mass) was elevated for total body 
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weight gain on HF diet, and for fat mass gain on both LF and HF diet in KO mice, relative to 
controls (Figure 24F, G). Interestingly, feed efficiency of KO mice for lean mass gain was not 
different from control mice on either diet (Figure 24G, H). Together, these data suggest that KO 
mice are more efficient at storing dietary fat as adipose. 
To determine if reduced energy expenditure contributes to increased fat mass gain in KO 
mice, energy expenditure (EE) was measured by indirect calorimetry. Interestingly, after 20 
weeks of HF diet exposure, daily EE (kcal) and EE normalized to total body weight (kcal/g BW) 
were not different in KO mice, relative to f/f mice (Table 6). At this time point, KO animals had 
similar total body weight but reduced lean mass (Table 6). When normalized per gram lean mass 
(kcal/g lean mass), KO mice exhibit a slight but significant elevation in EE over 24 hours relative 
to f/f mice (Table 6). During the measurement period, both daily food intake (kcal) and daily food 
intake normalized to body weight (kcal/g BW) were similar in KO and f/f controls. When daily 
Table . Effect of CNS PPARδ deletion on energy expenditure  
 
Energy expenditure (EE) and respiratory exchange ratio (RER) were measured over 24 
hours by indirect calorimetry in individually housed f/f and KO mice after 20 weeks on HF 
diet (n=4). Values for 24 hours, daily, EE (kcal) and food intake were also normalized to 
body weight and lean mass. Values represent mean ± SEM of each group and statistical 
significance is indicated by * (p<0.05), for comparisons between KO vs. f/f, same diet, 
using a Student’s t test.  
 
 f/f KO 
BW (g) 30.10 ± 1.44 30.90 ± 1.61 
lean mass (g) 19.05 ± 0.37 16.95 ± 0.42* 
Daily EE (kcal) 11.11 ± 0.18 11.01 ± 0.27 
Daily EE (kcal/g BW) 0.38 ± 0.01 0.35 ± 0.01 
Daily EE (kcal/g lean mass) 0.58 ± 0.01 0.65 ± 0.01* 
RER dark period 0.86 ± 0.01 0.82 ± 0.02 
Daily FI (kcal) 10.78 ± 0.24 10.43 ± 0.62 
Daily FI (kcal/g BW) 0.37 ± 0.01 0.37 ± 0.01 
Daily FI (kcal/g lean mass) 0.58 ± 0.02 0.64 ± 0.02* 
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food intake was normalized to lean mass (kcal/g lean mass), KO mice exhibited increased intake 
(Table 6).  
Consistent with elevated fat mass (Figure 24), KO mice had significantly higher plasma 
leptin levels after 33 weeks on LF diet and displayed a profound increase after HF feeding (Table 
7). Insulin was also elevated in KO mice but only on HF diet (Table 7), which was accompanied 
by a greater glucose intolerance in KO mice fed HF diet for 20 weeks, compared to HF fed f/f 
control mice (Figure 25A, B).  
 
 
Figure 25. Effects of CNS PPARδ deletion on glucose tolerance and corticosterone 
response. 
 
A) Glucose tolerance tests are illustrated, showing the changes in blood glucose levels after a 
glucose injection (1 g/kg BW, IP), for f/f and KO mice fed either a LF or HF diet for 20 
weeks (n=8-10). Mice were fasted for 4 hours and blood glucose levels were measured via 
tail blood at the indicated time points post glucose injection. B) Quantitation of area under the 
glucose curve (AUC) from glucose tolerance testing is shown for LF and HF fed f/f and KO 
mice. C) Plasma corticosterone levels in individually housed, chow fed, f/f and KO mice are 
illustrated. Blood was collected at nadir (8am), peak (5pm) or 30 minutes after a mild, 
restraint stress. Values represent the mean ± SEM. Statistical significance is denoted in panel 
B as 
a
 (
 
p<0.05, f/f vs. KO, same diet) and/or 
b
 (p<0.05, LF vs. HF, same genotype), as 
determined by two-way ANOVA and Bonferroni post test.  
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Effects of CNS PPARδ deletion on glucose tolerance and corticosterone response 
 
PPARδ is expressed throughout the CNS and is enriched in a number of other brain 
regions (248). To determine if neuronal loss of PPARδ resulted in dysregulation of the HPA axis, 
diurnal and stress induced levels of the hormone corticosterone, which is are associated with 
elevated adiposity and insulin resistance, were measured. Diurnal plasma concentrations (nadir 
and peak), and stress induced plasma corticosterone levels, did not differ between KO and f/f 
mice (Figure 25C), ruling out gross abnormalities in the HPA axis as a cause for elevated fat mass 
gain.  
 
Effects of CNS PPARδ deletion on brain lipid content and composition and hypothalamic 
gene expression of lipid metabolism genes  
 
Hypothalamic lipid accumulation/lipotoxicity is implicated in obesity (133). On LF diet, 
total levels of brain lipids (free fatty acid (FFA), diglyceride (DG), triglyceride (TG)) were not 
different between the genotypes (Figure 26A). Exposure to HF diet increased brain FFA content 
by 1.5-fold in f/f mice but did not alter brain FFA levels in KO mice, which had significantly 
lower levels of FFAs, relative to the HF fed f/f control mice (Figure 26A). HF diet also led to a 
Table 7. Effects of CNS PPARδ deletion on circulating concentrations of hormones and 
lipids 
 
Values represent mean ± SEM of each group (n=9-11) and statistical significance is 
indicated by.
a
 (p < 0.05, f/f vs. KO, same die) and/or , 
b
 (p< 0.05, LF vs. HF diet, same 
genotype), as determined by two-way ANOVA followed by Bonferroni post test. 
 
 
 
LF (10% kcal fat) HF (45% kcal fat) 
 f/f KO f/f KO 
insulin (ng/mL) 0.61 ± 0.08 1.00 ± 0.15 1.26 ± 0.26 2.21 ± 0.20
a,b
 
leptin (ng/mL) 5.7 ± 1.0 18.1 ± 2.3
a
 64.7 ± 21.4b 129.3 ± 11.4
a,b
 
FFA (mM) 0.66 ± 0.08 0.63 ± 0.06 0.82 ± 0.08 0.73 ± 0.03 
TG (mg/dL) 38.1 ± 3.0 53.1 ± 5.2
a
 63.6 ± 5.5
b
 46.5 ± 4.2 
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significant reduction in total TG levels in brains of KO mice, relative to the level of the LF fed 
KO group (Figure 26A).  
To determine if a transcriptional response was involved in the observed alterations in 
CNS lipid content, hypothalamic mRNA levels of several proteins involved in FFA uptake, 
lipoprotein lipase (LPL) and cluster of differentiation 36 (CD36), as well as triglyceride 
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Figure 26. Effects of CNS PPARδ deletion on brain lipid content and composition and 
hypothalamic gene expression of lipid metabolism genes.   
 
A) Total levels of triglyceride (TG), diglyceride (DG) and free fatty acid (FFA) extracted 
from total lipids from brains of f/f and KO mice (n=6-7) fed LF or HF diet for 33 weeks are 
reported. The quantity of individual FFA species (ng/mg tissue) making up brain FFA (C) 
and TG (E) fractions isolated from f/f and KO mice are depicted. Changes in hypothalamic 
mRNA levels of target genes involved in lipid uptake and storage (B; LPL, CD36, GPAT and 
DGAT), lipid synthesis (D; FAS, ACC, SCD) and fatty acid oxidation (F; ACO, PDK4, 
CPT1A, UCP2) were assessed by quantitative real-time PCR. Gene expression levels were 
normalized to endogenous RPL13A levels and are expressed as group mean±SEM relative to 
the level of the f/f, LF diet control group. Statistical significance is designated as 
a
 (p<0.05, 
f/f vs. KO, same diet) and/or 
b
 (
 
p< 0.05, LF vs. HF, same genotype), as determined by two-
way ANOVA and Bonferroni post test.  
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storage, glycerol-3-phosphate acyltransferase (GPAT) and diacylglycerol acyltransferase (DGAT) 
were quantified. On LF diet, hypothalamic mRNA levels of LPL, CD36 and DGAT were similar 
between f/f and KO groups, while GPAT gene expression increased by 2.4-fold in KO mice 
relative to the LF fed f/f control group (Figure 26B). Exposure to HF compared to LF diet did not 
alter expression of lipid uptake genes within either genotype (Figure 26B). On HF fed diet, LPL 
and CD36 mRNA levels were significantly elevated in KO mice relative to HF fed control levels 
(Figure 26B).  
Levels of individual FFA species were similar between genotypes on LF diet (Figure 
26C). In f/f control animals, HF diet increased the prevalence of SFAs, palmitate (16:0) by 1.5-
fold and stearate (18:0) by 1.4-fold, the MUFA oleate (18:1) by 1.2-fold, and the PUFA linoleate 
by 1.5-fold (Figure 26C). PPARδ deletion prevented HF diet-induce accumulation in these 
common dietary FFAs in the CNS (Figure 26C). Expression of key lipogenic enzymes, fatty acid 
synthase (FAS) and acetyl-CoA carboxylase (ACC), as well as stearoyl CoA desaturase 1 (SCD1) 
were determined to test the possibility that differences in lipogenesis could be involved. On LF 
diet, FAS gene expression was 3.1-fold higher in KO mice compared to f/f mice (Figure 26D). 
HF diet exposure increased FAS mRNA levels in f/f mice relative to LF diet levels, reaching 
levels roughly equivalent to that observed of LF diet fed KO mice(Figure 26D); however, HF diet 
did not additionally increase gene expression in KO mice relative to LF diet or HF fed f/f mice. 
Gene expression of SCD1 was also elevated by 2.4-fold in KO mice fed LF diet, compared to f/f 
controls on LF diet. Levels of SCD1 mRNA were not different between KO and f/f mice fed HF 
diet (Figure 26D), nor were they different between KO HF fed and KO LF fed mice. ACC mRNA 
levels did not differ among the groups on either diet (Figure 26D). 
In agreement with increased expression of FAS, GPAT and SCD1, KO mice had elevated 
18:1 levels in TG when on LF diet (Figure 26E). Transition to a HF diet resulted in significantly 
reduced 16:0 and 18:1 levels in TG of KO animals (Figure 26E). To determine if increased fatty 
acid oxidation might contribute to decreased FFA accumulation in brains of KO mice fed HF diet, 
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mRNA expression levels of  key proteins involved in lipid  catabolism we quantified. On LF diet, 
pyruvate dehydrogenase kinase 4 (PDK4) gene expression increased by 1.7-fold in KO mice 
(Figure 26F). HF feeding increased expression of UCP2 in f/f mice by 2.4-fold, but did not alter 
UCP2 expression in KO mice (Figure 26F). On HF diet, KO mice had ~2-fold greater expression 
of two markers of mitochondrial fatty acid oxidation, carnitine palmitoyltransferase 1A (CPT1A) 
and PDK4, compared to f/f mice fed HF diet. Expression of acyl-CoA oxidase (ACO), a marker 
of peroxisomal fatty acid beta-oxidation, did not differ among the groups on either diet (Figure 
26F). As a whole, these data suggest that PPARδ contributes to the regulation of expression of 
lipid metabolism genes in the hypothalamus, thereby affecting both CNS basal lipid metabolism 
and responses to increased dietary lipid exposure.  
 
CNS PPARδ KO mice are resistant to diet-induced hypothalamic inflammation 
Agonists of PPARδ prevent lipotoxicity and have anti-inflammatory effects in the CNS 
(263, 308). In order to determine if loss of PPARδ increases inflammatory signaling in 
hypothalamus, mRNA levels of the inhibitor of NF-κB, IκBα, and two transcriptional targets of 
NF-κB, the pro-inflammatory cytokines, IL-6 and IL-1β (378) were assessed. On LF diet, IκBα 
levels in hypothalamic total cell protein extracts were reduced by 25% in KO mice relative to LF 
fed f/f mice (Figure 27A). Exposure to HF diet reduced IκBα protein levels by ~40% in f/f mice, 
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as reported in several DIO models (133, 137). HF diet exposure failed to reduce IκBα protein 
levels beyond the lower levels found on LF diet in hypothalamus of KO mice (Figure 27A), thus 
f/f and KO mice both had protein levels of IκBα on HF diet. Consistent with IκBα data and 
activation of pro-inflammatory signaling, KO animals have increased hypothalamic IL-6 and IL-
1β gene expression on LF diet relative to LF fed f/f controls (Figure 27B, C). HF diet increased 
mRNA levels of IL-6 and IL-1β in f/f control mice, while KO mice were protected from a further 
HF diet induced elevation of hypothalamic cytokine gene expression (Figure 27B, C).  
 
 
 
 
 
Figure 27. Effects of CNS PPARδ deletion on diet-induced hypothalamic inflammation. 
 
Protein and mRNA were isolated from bisected sections of mediobasal hypothalamus of f/f 
and KO mice fed LF or HF diet for 33 weeks. A) Total hypothalamic protein extracts were 
subjected to Western blot analysis using an antibody directed against total IκBα. Levels of β-
tubulin were determined and used as a loading control. Densitometery of blots yielded 
relative intensity as a measure of protein levels (n=6). Insert of A shows a representative 
Western blot. Hypothalamic mRNA levels of inflammatory cytokines IL-6 (B) and IL-1β (C) 
in f/f and KO mice measured by RT-PCR after 33 weeks of Lf or HF diet are shown. Target 
gene mRNA levels were normalized to endogenous RPL13A levels. Values are represented 
as group mean ± SEM relative to the LF f/f control group. Statistical significance is 
designated as 
a
 (p<0.05, f/f vs. KO, same diet), and/or 
b
 (p<0.05, LF vs. HF, same genotype), 
as determined by two-way ANOVA and Bonferroni post test.  
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CNS PPARδ deletion alters regulation of hypothalamic neuropeptide gene expression 
To identify mechanisms by which loss of neuronal PPARδ increases DIO susceptibility, 
hypothalamic mRNA levels of NPY and POMC, key regulatory neuropeptides were determined. 
On LF diet, NPY gene expression increased by 1.8-fold in KO mice (Figure 28A), which was 
consistent with the basal phenotype of KO animals on a chow diet (Figure 23). HF diet exposure 
doubled NPY mRNA levels in f/f mice, but did not further increase NPY mRNA levels in KO 
mice (Figure 28A). POMC mRNA levels did not differ between KO and f/f mice fed LF diet 
(Figure 28B). On HF diet, POMC expression increased 2.4-fold in f/f mice, but was not altered by 
HF diet exposure in KO mice (Figure 28B).  
 
 
 
 
 
Figure 28. Effects of CNS PPARδ deletion on hypothalamic neuropeptide mRNA 
levels.  
 
Hypothalamic mRNA levels of neuropeptides, NPY (A) and POMC (B), in f/f and KO mice 
(n=6-7) fed LF or HF diet for 33 weeks were assessed by quantitative RT-PCR. Target gene 
mRNA levels were normalized to endogenous RPL13A levels. Values represent the mean ± 
SEM. Statistical significance is designated by 
a
 (p<0.05, f/f vs. KO, same diet) and/or 
b
 
(p<0.05, LF vs. HF, same genotype), as determined by two-way ANOVA and Bonferroni 
post test. 
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CNS PPARδ deletion leads to increased hypothalamic PPARγ and PPARα expression. 
I next evaluated hypothalamic mRNA expression levels of all three PPAR isoforms and 
mRNA levels of several target genes of these transcription factors to determine if PPARα and 
PPARγ could have altered brain lipid content, inflammation and gene expression in PPARδ KO 
mice. Gene deletion of PPARδ resulted in a ~90% reduction in PPARδ mRNA levels irrespective  
of diet (Figure 29). In line with similar CNS lipid content and hypothalamic gene expression of 
LF diet, expression levels of PPARα and PPARγ mRNA were similar between f/f and KO groups 
on LF diet (Figure 29). Consumption of HF diet increased PPARα gene expression by 1.6-fold in 
KO, but not in f/f mice, relative to the LF fed f/f control group (Figure 29). PPARγ gene 
 
Figure 29. Effects of CNS PPARδ deletion on hypothalamic PPARγ and PPARα 
gene expression.  
 
Hypothalamic mRNA levels of PPAR isoforms in f/f and KO mice fed LF or HF diet 
for 33 weeks was assessed by quantitative real-time PCR. PPARδ, PPARγ and PPARα 
levels were normalized to endogenous RPL13A levels, and expressed relative to that of 
the f/f, LF fed group. Values represent group mean±SEM (n=6-7). Statistical 
significance is designated by 
a
 (p<0.05, f/f vs. KO, same diet) and/or 
b
 (p<0.05, LF vs. 
HF, same genotype), as determined by two-way ANOVA and Bonferroni post test.  
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expression was 2.6-fold higher in hypothalamus of HF fed KO mice relative to HF fed f/f mice 
(Figure 27).  
As you may recall in CNS PPARδ KO mice, mRNA levels of the PPARδ target gene 
UCP2, were not increased by fasting (Figure 23C) or HF diet (Figure 26F). In the context of 
elevated PPARα mRNA levels in KO mice on HF diet, the PPARα target gene, CPT1A, 
increased, although mRNA levels of another target gene of PPARα, ACO, did not differ between 
genotypes (Figure 26F). Gene expression of PPARγ target genes, LPL and CD36, were also 
elevated in the presence of higher PPARγ gene expression in HF fed KO mice (Figure 26B). 
 
Summary 
In peripheral tissues, PPARδ is a known regulator of lipid oxidation, and thereby, is 
thought to reduce inflammation and promote insulin sensitivity (223, 231, 379). Relatively less is 
known about PPARδ function in the CNS, where it has been implicated in neuroprotection by 
reducing inflammation and oxidative stress (reviewed in (323). The purpose of these experiments 
was to confirm a role for neuronal PPARδ in energy homeostasis, and tested the hypothesis that 
PPARδ acts to reduce lipid accumulation and inflammation, opposing the development of 
biochemical resistance to homeostatic signals such as leptin and genetic deletion, would therefore 
be predicted to lead to obesity. Consistent with this hypothesis, neuronal PPARδ deletion results 
in higher adiposity on LF diet and a profound susceptibility to DIO. Surprisingly, the results of 
these studies did not provide evidence favoring a role for PPARδ in stimulation of neuronal FFA 
oxidation and reduction of lipotoxic intermediates. Rather, loss of PPARδ led to reductions in 
CNS FFA accumulation accompanied by a similar attenuation in hypothalamic inflammation in 
response to dietary fat exposure that could not be attributed to alterations in peripheral 
inflammatory mediators (not shown). Several mechanisms may explain this finding, including a 
robust upregulation of PPARγ, and perhaps, PPARα function. Recently, brain PPARγ activation 
has been implicated `in hyperphagia, weight gain and obesity in rodents (242, 366), potentially 
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consistent with these findings. These findings reveal a previously underappreciated role for 
neuronal PPARδ in the regulation of body composition, obesity susceptibility, and in suppression 
of hypothalamic PPARα and PPARγ expression.  
Neuronal deletion of PPARδ results in a complex phenotype characterized by increased 
fat mass and reduced lean mass on a LF diet. KO mice fed LF diet were more efficient at storing 
fat mass despite lower total food intake. In addition to recapitulating an obesity-like phenotype 
characterized by higher adiposity on a LF diet, genetic loss of PPARδ function potentiates fat 
mass gain on a HF diet. Excess fat mass accrual occurred, while mice where on a HF diet, in the 
absence of large differences in food intake or energy expenditure (normalized to BW). When 
these parameters were normalized to lean mass, KO mice consumed more calories and exhibited 
higher energy expenditure after 20 week on a HF diet. Therefore, preferential disposition of 
consumed calories towards adipose tissue storage, along with subtle imbalances between food 
intake and energy expenditure that are below the detection limits of the methods that were used to 
measure these parameters, contribute to excess fat mass gain in KO mice over many weeks of HF 
feeding.  
Increased brain cytokine gene expression on LF diet and leptin resistance in chow fed 
mice indicates that PPARδ has anti-inflammatory activity and supports basal leptin sensitivity. 
Coinciding with leptin resistance and mild hyperleptinemia, KO mice exhibit elevated basal NPY 
gene expression on LF diet. A possible explanation for why NPY gene expression is decreased 
during fasting, while POMC gene expression is not altered, may be a blunted induction of UCP2 
expression that results in elevated levels of ROS, which has been shown to repress NPY gene 
expression while simultaneously promoting POMC gene expression (380). The regulatory effects 
of ROS on neuropeptide expression are abrogated by UCP2 mediated uncoupling of the 
mitochondrial proton gradient (373), and published studies implicate a protective role for UCP2 
in neuroinflammatory disease and hypothalamic inflammation (381) via its ability to attenuate 
ROS production. Mice lacking the gene for UCP2 have elevated levels of basal NF-κB activation 
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(367) and increased cytokine expression after ischemic injury (382). PPARδ KO mice also 
displayed elevated hypothalamic expression of several proinflammatory cytokine genes on LF 
diet, supporting the hypothesis that PPARδ has an important anti-inflammatory function.  
Ectopic lipid accumulation and low-grade inflammation are linked to insulin and leptin 
resistance in the CNS (133, 325, 329) and activation of PPARδ attenuates lipotoxicity in 
peripheral tissues (231, 234, 236, 238, 308). It was somewhat surprising then, to find that KO 
mice were resistant to CNS lipid accumulation and further inflammation even after prolonged HF 
feeding despite a baseline increase in markers of inflammation on LF diet. On LF diet, KO mice 
displayed a reduction in IκBα, a key inhibitor of NF-κB activity, and an increase in two key pro-
inflammatory targets of NF-κB regulation, IL-6 and IL-1β. This basal hypothalamic inflammatory 
phenotype was not further altered with HF diet in KO mice. Limited FFA oxidation does occur in 
the CNS, and may play a particularly important role in homeostatic feeding centers (383). Gene 
expression of CPT1A, which catalyzes the rate limiting step of beta-oxidation and is implicated in 
neuronal fatty acid sensing (243), is induced by PPARα activation, providing a possible 
explanation for the reduction in CNS FFA accumulation in KO mice fed HF diet. 
If changes in PPAR gene expression have biological effects on lipid metabolism and 
inflammation, we would expect to find alterations in the expression of target genes of these 
receptors as well. There were consistent changes in the expression of several isoform specific 
target genes of PPARα (CPT1A) and PPARγ (LPL), which are known to be induced by specific 
chemical agonists of these receptors in the CNS (242, 244). PPARα expression was slightly 
elevated, while PPARγ was more significantly elevated in brains of KO mice on HF diet. An 
additional target gene of PPARγ, CD36, also showed elevated expression in KO mice. Deletion 
of PPARδ in cardiomyocytes was shown to cause a similar induction of PPARα and PPARγ, as 
well as their target genes involved in fatty acid oxidation (384). These finding are consistent with 
evidence from in vitro studies that show PPARδ represses both the expression and activation of 
these other PPAR isoforms (276, 385). Activation of hypothalamic PPARα and/or PPARγ has 
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been implicated in weight gain and obesity, which is consistent with the elevated adiposity and 
greater susceptibly to DIO observed with PPARδ KO mice. Thus, these data reveal a previously 
underappreciated role for neuronal PPARδ in the regulation of body composition, neuropeptide 
expression, leptin sensitivity, obesity susceptibility, and suppression of hypothalamic PPARα and 
PPARγ gene expression. 
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CHAPTER VI 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
The overarching and major themes presented in this dissertation are: 
I: Dietary fatty acid composition is an important determining factor of cellular and 
metabolic responses to dietary fat intake.  
II: PPARδ is a target of MUFAs in neurons and a mediator of cellular and metabolic 
responses.  
III: PPARδ in neurons has a role in the regulation of energy balance, fuel partitioning, 
and in homeostatic responses to metabolic challenges, as determined by studies in a 
neuronal genetic deletion model.  
The focus of this chapter will be to place these three themes into a larger context of an obesogenic 
environment, and cellular mechanisms to protect against metabolic dysfunction. 
The ability of dietary fat to promote insulin resistance in peripheral tissues has been 
appreciated for some time (119, 386, 387). Dietary fat my also contribute to obesity pathogenesis 
more so than other macronutrients (123). These effects are thought to be mediated primarily by 
SFAs, via their ability to induce lipotoxicity and inflammation in key regulatory neurons and 
brain regions (such as mediobasal hypothalamus), which contributes to positive energy balance 
and weight gain (133, 137, 313, 388). There is extensive epidemiologic evidence that MUFAs 
improve insulin sensitivity (187, 193, 332, 358, 389), promote weight loss (341, 354, 390) and 
reduce inflammation (314, 335, 391, 392).  
Chapter III explored the role of dietary fat composition in DIO pathogenesis and diet-
induced hypothalamic inflammation. A HF diet, rich in MUFAs, compared to a HF diet rich in 
SFAs promoted less weight gain (Figure 12), and did not activate markers of inflammation, ER or 
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oxidative stress in the hypothalamus (Figure 13). Similar caloric and fat contents of these two HF 
diets, coupled with similar levels of food intake between groups of rats consuming the HF-SFA 
and HF-MUFA diets, suggested that structural differences between MUFAs and SFAs may play 
an important role in the differential effects. This led to the hypothesis that dietary MUFAs may 
interact with a fatty acid sensor, potentially in the hypothalamus, that could protect against 
hypothalamic stress and inflammation, as well as promote insulin sensitivity.  
Several lines of evidence suggested that PPARδ could be involved in the beneficial 
effects of the HF-MUFA on hypothalamic inflammation and DIO. At the mRNA level, MUFAs, 
consumed in the diet increased expression of PPARδ as well as a key neuronal PPARδ target 
gene, UCP2 (238), in the hypothalamus. The biological effects of PPARs are mediated via 
transcriptional regulation of target gene expression (213), therefore it was important that 
increased expression of a known PPARδ target gene, UCP2 could be detected. A specific-agonist 
(GW0742) of PPARδ was administered via ICV cannula, into the 3rd ventricle of rats to 
recapitulate the effect of MUFAs, confirming UCP2 as a specific CNS gene target of ligand-
activated PPARδ in the hypothalamus.   
The findings from in vitro studies described in chapter IV confirmed PPARδ as a 
molecular mediator of the beneficial effects of MUFAs on ER and oxidative stress, inflammation 
and insulin signaling. In addition to inducing stress and inflammation, antagonism of PPARδ with 
GSK0660 prevented ligand induced expression of the PPARδ target gene UCP2. This data 
suggested that MUFAs are protective via transcriptional activation of PPARδ and expression of 
target genes, such as UCP2, that encode proteins capable of opposing lipotoxicity. Thus, the next 
important question to address is if this occurs in vivo as well. However, a limitation of the genetic 
targeting approached used to disrupt PPARδ function, through deletion of the DBD, may lead to 
depressression of some target genes (276), as well as compensatory upregulation of other PPAR 
isoforms (276, 385). Therefore, to genetically recapitulate the molecular consequence of the 
antagonist GSK0660 in an in vivo system, these studies could be performed in mice that 
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conditionally express a dominant negative transgene lacking the carboxy terminal LBD of PPARδ 
(393). If the effects of MUFAs are dependent on transcriptional activation of PPARδ, 
consumption of the HF-MUFA diet would be expected to lead to  a similar increase of weight 
gain and adiposity as the more obesogenic HF-SFA diet in mice that express a dominant negative 
form of PPARδ.  
Evidence from human feeding experiments suggests that dietary fat, more so than 
carbohydrate or protein, promotes triglyceride storage in adipose tissue (394, 395). However, the 
findings from cell culture experiments suggested PPARδ acts to maintain insulin sensitivity in 
neuronal cells, in the presence of high levels of mixed fatty acids. This raises the possibility that 
PPARδ could be involved in the beneficial effects of very low carbohydrate, high fat diets, such 
as Atkins on weight loss (396). Mice expressing the dominant negative form of PPARδ could be 
fed an Atkins style diet containing high levels of protein and fat consisting of a mixture of SFAs 
and MUFAs with small amounts of carbohydrates, to determine if PPARδ activation mediates the 
beneficial effects of low carbohydrate diets on weight loss. At the conclusion of this study, 
biochemical markers of hypothalamic ER stress (p’PERK), oxidative stress (p’p66shc) and 
inflammation (IL-6 mRNA) would also be predicted to be elevated in mice that express the 
dominant negative form of PPARδ. Positive findings will support the conclusion that MUFAs 
protect against SFA induced obesity and hypothalamic stress and inflammation at least in part, 
through transcriptional activation of PPARδ (Figure 31B).  
Neuronal PPARδ deletion did not affect brain size, neuronal density or gross CNS 
morphology, nor did if cause observable behavioral abnormalities. Based on this evidence, CNS 
development appears to be normal in KO mice. However, nestin mediated deletion occurs at 
embryonic day (E) 7.5-8.0 and recombination of a floxed allele is detectable at E15.5 (369). 
Peters et al reported that germ line deletion of the LBD of PPARδ leads to reduced brain size and 
myelination defects in the corpus collosum of a small percentage (30%) of male mice (254). To 
investigate the effects of PPARδ deletion on CNS development, an inducible system such as the 
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tetracycline-responsive operator (Tet-O) (397) could be used to control when nestin-cre is 
expressed, and thus when PPARδ is deleted.  
 The neuronal PPARδ KO model used in these studies revealed a previously 
unappreciated role of PPARδ in CNS. The phenotype however, is complex and many questions 
remain regarding the role of CNS PPARδ in DIO susceptibility and regulation of fuel partitioning 
and body composition. A major limitation of the neuronal KO model is the inability to isolate the 
type of neurons, the neurological system or even the brain regions that are involved in the 
phenotype. To localize the effects of gene deletion, the floxed allele of PPARδ could be deleted 
by stereotaxic delivery of an adeno-associated virus expressing Cre recombinase (398). Several 
lines of evidence suggested that PPARδ is critical for the function of hypothalamic neurons 
involved in energy balance. Therefore a future direction could be to determine if targeted deletion 
in the hypothalamus can recapitulate the abnormal feeding and neuropeptide responses to fasting 
found in the neuronal KO mouse. Biochemical analysis could be used to determine if loss of 
PPARδ expression in the hypothalamus is sufficient to cause oxidative stress, ER stress, and 
inflammation, and if so, whether the effects lead to changes in hormone sensitivity. A follow up 
experiment could determine if chemical modulation of these pathways (ER stress, oxidative stress 
or inflammation) or conditional overexpression of a PPARδ target gene, such as UCP2 is 
sufficient to rescue the phenotype caused by regional deletion of PPARδ. These proposed 
experiments will be described in more detail later in this chapter. 
  In neuronal PPARδ KO mice on both LF and HF diet, excess fat mass accrual occurred in 
the absence of large differences in food intake or energy expenditure (normalized to either BW or 
lean mass). Therefore, preferential disposition of consumed calories towards adipose tissue 
storage coupled with likely subtle imbalances between food intake and energy expenditure 
contribute to excess weight gain in these animals over time. Loss of PPARδ function with 
GSK0660 led to insulin resistance in mHYPO E42 cells, and leptin resistance in neuronal PPARδ 
KO mice. An important question to address in future studies is if PPARδ modulates insulin and 
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leptin sensitivity in neuronal circuits outside the hypothalamus that could lead to positive energy 
balance. The reinforcing aspects of dopamine release on food reward are modulated by peripheral 
adiposity signals acting in brain regions associated with reward and cognition (70) and resistance 
to these hormones may contribute to feeding dysregulation in obesity (74). PPARδ mRNA 
expression is reduced after HF diet feeding in the striatum (71), which contains postsynaptic 
neurons involved in the mesolimbic dopamine reward pathway (62, 63). To determine if PPARδ 
affects the neurocircuitry involved in reward, neuronal PPARδ KO mice could be assessed using 
a conditioned place preference paradigm (399) to determine if the rewarding properties of high-
fat diet are increased in the absence of PPARδ  expression. 
 There is evidence that disruption of the circadian rhymicity of feeding leads to increased 
adiposity and weight gain despite similar food intake in mice (400). Therefore, it is possible that 
neuronal PPARδ KO mice gain weight due to alterations in feeding patterns, which would not be 
detected by measurements of cumulative biweekly or daily food intake.  Obesity is associated 
with perturbations in the expression of clock genes controlling circadian rhythms involved in 
energy homeostasis and feeding patterns within the caudal brainstem nucleus of the solitary tract 
(401). These changes in circadian gene expression occurred in the presence of increased 
expression of PPARα, a gene that is normally repressed by PPARδ (274). To determine if 
alterations in the circadian feeding rhythms may contribute to increased adiposity in neuronal 
PPARδ KO mice, a meal pattern analysis could be performed using an advanced phenotyping 
system such as the Promethion System (Sable Systems Inc., Las Vegas, NV) which is available in 
the Vanderbilt MMPC.    
 Other regions of the brain which may be affected by loss of PPARδ could be identified 
by assessing UCP2 expression by in situ analysis after HF-MUFA diet exposure. These may 
include the hippocampus, which expresses UCP2 (402) and PPARδ (248) and where both genes 
may be involved in protection against oxidative stress (349, 403). Leptin signaling in this region 
reduces food intake (404) while damage to the hippocampus by lesioning interferes with energy 
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and body weight regulation, potentially due to dysregulation of food related memory processing 
(405). Collectively, positive findings following regional deletion of PPARδ through bilateral 
stereotaxic delivery of an adeno-associated virus expressing Cre recombinase, along with 
behavioral analysis studies will help determine potential cell types and neuronal signaling 
networks involved. Following identification putative targets, specific cre driver lines can be used 
to localize deletion of the floxed allele to a specific cell type.  
Oxidative stress is highly associated with inflammation, via activation of NF-κB (171, 406) 
and has been linked to insulin resistance in numerous peripheral tissues (161, 162, 174, 175, 177, 
316, 407-411). Oxidative stress is also a common feature of neurodegenerative disease states 
(164, 165, 167). PPARδ agonists have neuroprotective qualities that may be attributed to 
reductions in ROS production and protection from the deleterious effects of oxidative stress 
(323). Thaler et al observed morphological changes in mitochochondria after 1 week of HF 
feeding (313) suggestive of mitochondrial dysfunction (412), however there are no published 
reports of oxidative stress measured in hypothalamus of DIO animals. Therefore, superoxide 
levels were determined in medialbasal hypothalamus of Long Evans rats after 1 week of ad 
libitum feeding with LF or HF-SFA diet. There was a profound increase in mitochondrial 
superoxide accumulation in the hypothalamus of rats fed HF-SFA diet, compared to LF diet 
(Figure 30), as determined with the mitochondrial superoxide specific probe, MitoSOX. 
Additional groups of rats received LF or HF-SFA diet as well as a single daily bolus injection of 
the superoxide scavenger, mitoTEMPO  (1.5mg/kg/day, IP) (413), or vehicle during the one week 
study period to demonstrate that mitochondria were indeed the source of superoxide. 
MitoTEMPO did not alter hypothalamic superoxide levels in rats fed LF diet (Figure 30).  In rats 
fed HF-SFA diet, MitoTEMPO treatment prevented hypothalamic mitochondrial superoxide 
accumulation, compared to HF-SFA fed, vehicle treated rats (Figure 30, p<0.05). Collectively, 
this data provides evidence that hypothalamic mitochondrial superoxide accumulation is a feature 
of early DIO and supports a model where SFA induced hypothalamic mitochondrial ROS 
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accumulation may promote ER stress and inflammation resulting in insulin and leptin resistance, 
thereby contributing to dysregulated energy homeostasis and DIO (Figure 31A). 
 
 PPARδ activation with GW0742 reduced palmitate induced IL6 expression in mHYPO 
E42 cells, while loss of PPARδ function, in vitro with GSK0660, and in neuronal PPARδ KO 
mice, increased IL6 and IL-1β expression. Changes in cytokine expression were accompanied by 
similar elevations in activation of the ER stress marker p’PERK and evidence for increased ROS 
production (not shown). There is some evidence that ER stress and inflammation are intimately 
linked via the IKK-NF-ΚB pathway (152). The temporal sequence in which these pathological 
events occur in DIO is not known, although chemical inhibitors of ER stress (414) or genetic 
 
Figure 30. One week of high fat diet leads to hypothalamic mitochondrial oxidative stress.  
 
Mitochondrial oxidative stress was measured in medialbasal hypothalamus of Long Evans rats after 
1 week of ad libitum feeding of LF or HF diet with and without MitoTEMPO treatment. ROS 
levels were quantified using the mitochondria specific superoxide probe MitoSOX. Values 
represent group mean±SEM (n=6). Statistical significance is designated as 
a
 (p<0.05 vs. LF - 
MitoTEMPO) and/or 
b
 (p<0.05 vs. HF-SFA - MitoTEMPO), as determined by one-way ANOVA 
and post-hoc Tukey’s multiple comparison test.  
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deletion of IKK, the upstream kinase involved in activation of the NF-κB pathway (152, 415) 
improve hypothalamic insulin and leptin sensitivity in DIO animals. Oxidative stress can 
contribute to insulin resistance through activation of ER stress (416) as well as activation of the 
IKK-NF-κB pathway (171). Thus the next key question is whether reducing oxidative stress will 
prevent ER stress and inflammation caused by loss of PPARδ function with the PPARδ inhibitor 
GSK0660. The role of oxidative stress can be determined in mHYPO E42 cells using 
polyethylene glycol conjugated superoxide dismutase (PEG-SOD) (417) or MitoTEMPO to 
reduce cytoplasmic or mitochondrial superoxide levels, respectively.  
As shown in chapter III, 1 week of HF diet feeding was associated with elevated IL-6 and 
slightly lower UCP2 mRNA levels. Superoxide levels were also increased at this time point 
(Figure 30). Data implicate UCP2 in neuroprotection, reduction of CNS oxidative stress and 
protection from neuroinflammation and neuronal injury (381, 403, 418). Thus, the next question 
is whether UCP2 expression is sufficient to restore the protective effects of PPARδ activation, 
which could be tested in mHYPO E42 cells treated with a viral expression vector to restore UCP2 
expression following exposure to mixed FFAs and GSK0660.   
Consistent with a primary role for neuronal PPARδ to regulate UCP2 in response to fatty 
acids, fasting failed to increase hypothalamic expression of UCP2 in neuronal PPARδ KO mice. 
This was accompanied by dramatic differences in neuropeptide gene expression (both NPY and 
POMC) at baseline, and a complete absence of compensatory responses to fasting. ROS serve as 
a nutrient signal and second messenger in hypothalamic neurons, where they are known to repress 
NPY while simultaneously promoting POMC gene expression (380). The regulatory effects of 
ROS, to repress NPY neuronal activation and neuropeptide expression, are abrogated by UCP2 
mediated mitochondrial uncoupling (116). The blunted fasting induced UCP2 and NPY 
expression as well as impaired refeeding in this neuronal PPARδ KO model are similar to effects 
observed with a global PPARδ KO model (259). This evidence suggests that PPARδ regulates 
neuropeptide expression indirectly, via control of UCP2 expression and ROS production. To 
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address this critical question, UCP2 expression could be restored through microinjection of a viral 
vector expressing UCP2 (419) into the hypothalamus, to determine if it could reverse the effects 
of PPARδ deletion on neuropeptide expression and feeding responses as well as increased basal 
stress and inflammation present in KO mice on LF diet. Superoxide levels and UCP2 protein 
content should also be measured, to confirm that an increase in UCP2 mRNA leads to increased 
protein and measurable effects on ROS production. 
An intriguing observation was that in PPARδ KO mice, HF diet exposure did not further 
increase CNS inflammation or ER stress beyond that observed with LF diet. These effects may be 
attributed to a robust upregulation of PPARγ which has well documented anti-inflammatory 
effects (256, 289). In addition to a marked increase in PPARγ expression, expression of two 
PPARγ target genes, LPL (217) and CD36 (420) were also increased. There was also evidence for 
increased activation of PPARα on HF diet, as evidenced by increased expression of the target 
gene CPT1A (244) and reduced lipid accumulation. These findings are consistent with evidence 
from in vitro studies that show PPARδ represses both the expression and activation of other 
PPAR isoforms (276, 385). In order to quantify the effect of PPARγ upregulation, the following 
experiments could be done.  
Weight gain is a side effect of the TZD class of PPARγ ligands (421), which has been 
attributed to effects of activation of PPARγ in the CNS (241, 242). This evidence suggested that 
PPARγ was a potential mediator of elevated adiposity and increased susceptibility to DIO in 
PPARδ KO mice. The basal phenotype of increased adiposity in PPARδ KO mice is greatly 
augmented upon exposure to HF diet which suggests that PPARγ activation by dietary fatty acids 
(242) contributes to obesity in this model. If this theory is correct, treatment of neuronal PPARδ 
KO mice with a chemical PPARγ antagonist should attenuate the rate at which KO mice accrue 
fat mass on a HF diet.  
While hypothalamic inflammation was elevated in the basal state (LF diet), KO mice 
exhibited resistance to further HF diet induced hypothalamic inflammation. PPARγ has potent 
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anti-inflammatory effects via transrepression of NF-κB and inhibition of cytokine expression 
(290), raising the possibility that dietary fat provides ligands that  activate PPARγ, which in turn 
reduces inflammation in KO animals. Based on this, antagonist treatment would be expected to 
increase inflammation in KO mice on HF diet. Lastly, a double PPARγ/PPARδ knockout 
approach may be required to reveal the full range of the effects of PPARγ modulation of the 
PPARδ phenotype. 
A number of dual PPAR agonists have been developed, that retain the beneficial effects 
of TZDs but cause less weight gain (422-425). This can be achieved with compounds that are 
dual agonists of PPARδ, the activation of which opposes weight gain through increased 
expression of target genes involved in mitochondrial function and lipid oxidation (346). 
Therefore, based upon several lines of evidence, both in the literature and presented here, PPARδ 
may reduce inflammation indirectly, through upregulation of protective target genes that oppose 
lipotoxicity. In addition to selectively amplifying the expression of protective PPARδ target genes 
that also may promote fat oxidation, dual agonists minimize the fat storage promoting potential of 
PPARγ by acting as partial agonists, which have weak transactivation potential of adipogenic 
gene expression (423). The insulin sensitizing effects of partial PPARγ agonists may therefore be 
attributed to transrepression of inflammatory gene expression (289). There is some data to 
suggest that partial loss of PPARγ transactivation with a dual PPARγ/RXR antagonist (426) or in 
heterozygous PPARγ KO mice (427), is associated with weight loss, resistance to DIO, and 
improved insulin sensitivity. Posttranslational modification of the PPARγ LBD by the action of  
small ubiquitin-like modifier proteins (SUMO), reduces inflammation despite preventing RXR 
from associating with PPARγ after ligand binding, which commits it to the transrepression 
pathway (428). Therefore, development of a dual agonist compound that could promote 
transactivation of PPARδ target genes and also selectively commit PPARγ to the transrepression 
pathway would have extensive therapeutic potential as an anti-inflammatory weight loss and 
insulin sensitizing drug. No compounds like this currently exist, although one approach may be to 
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design a ligand that can block RXR binding to PPARγ through steric hindrance of the region of 
the LBD that contains the RXR docking site (283).  
The PPARα target gene CPT1 has been implicated in impaired fuel sensing and 
hyperphagia in response to HF diet (383, 429) and in peripheral tissues, is known to augment 
mitochondrial oxidative stress and superoxide production (174). Transient oxidative stress 
damages mitochondria (430) which may explain lipid accumulation after prolonged HF feeding in 
wild type animals and as reported previously (133). However, the blunted FFA accumulation 
found in KO mice on HF diet did not support the inflammation based model (325) that also 
suggests toxic lipid accumulation is involved in DIO pathogenesis (133). Lack of inflammation 
and blunted lipid accumulation in neuronal PPARδ KO mice on HF diet, are consistent with an 
alternative model that suggests that HF diet may lead to loss of hypothalamic fuel sensing which 
promotes obesity, possibly through alterations in neuropeptide expression and neuronal energy 
metabolism (383, 429). While the hypothalamic gene expression profile of PPARδ KO mice 
suggests increased mitochondrial fatty acid oxidation, peroxisomal fatty acid oxidation would 
also explain blunted FFA accumulation in KO animals (196). DIO leads to peroxisome 
proliferation in POMC neurons which has been attributed to PPARγ activation in DIO (380). This 
model is also consistent with upregulation of UCP2 expression in wild type mice on HF diet, 
which would be predicted to contribute to increased food intake (117). Collectively, the findings 
in neuronal PPARδ KO mice on HF diet support a model where protective responses that restrain 
stress, inflammation and lipid accumulation may contribute to obesity pathogenesis, and that 
these effects may be mediated by acquired loss of PPARδ repression and upregulation and/or 
activation of PPARα and PPARγ. 
An integrated model, based upon the individual findings presented in this dissertation, 
and discussed in this chapter, for the roles of PPAR, UCP2, ROS and compensatory upregulation 
of other PPAR isoforms will be described next (Figure 31). The inability to upregulate UCP2 in 
response to elevated FFA levels may augment ROS production that acutely acts to disrupt 
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neuropeptide expression causing abnormal feeding responses. Chronic exposure to ROS results in 
hypothalamic oxidative stress, which then activates IKK-NF-ΚB and promotes ER stress, which 
may contribute to insulin and leptin resistance in neuronal PPARδ KO animals on LF diet. Basal 
inflammation promotes leptin and insulin resistance, which could then contribute to higher basal 
adiposity in KO mice. Exposure to circulating FFAs, during fasting or HF feeding, may lead to 
unregulated activation of PPARα, and increased fatty acid oxidation and blunted lipid 
accumulation. Without the protective effects of PPARδ, the effects of FFAs on oxidative and ER 
stress and inflammation are augmented.  However, PPARδ is also a known repressor of the 
PPARγ, which becomes activated and may act to reduce inflammation but also could promote 
DIO through a yet to be determined mechanism. Thus, in the absence of PPARδ, the normally 
protective responses of these two PPAR isoforms appear to be unregulated, effectively preventing 
lipotoxicity while promoting obesity.  
  
Conclusions 
Collectively, my findings show that neuronal PPARδ expression is critical to the function of 
regulatory neurons involved in energy homeostasis. Profound dysregulation of homeostatic 
responses to fasting and refeeding, an experimental maneuver to amplify potential defects in the 
system, reveal UCP2 as a potential molecular mediator of the phenotype. The inability to 
upregulate UCP2 in response to normal physiological stressor, and after feeding, suggests that 
PPARδ may play a pivotal role, regulating the delicate balance between redox control of feeding 
regulation and protection from oxidative stress (Figure 31). More work is needed to identify the 
brain regions and neuronal cell types involved in the phenotypic abnormalities and also, to 
determine if oxidative stress contributes to hypothalamic inflammation and leptin resistance in 
DIO.  
Future studies will be required to understand compensatory changes in other PPAR isoforms 
in this complex phenotype. Given multiple complex modes of regulation of multiple target genes, 
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including other PPAR isoforms (269, 431), an understanding of the relevance of isoform 
compensation and crosstalk will require studying mice with genetic deletion of PPARδ and 
PPARγ. PPARs are transcriptional targets of dietary lipids (or metabolites thereof) and are likely 
to shed important new light upon plausible mechanisms by which a changing dietary environment 
may multi-factorally enhance susceptibility to obesity. More work is clearly needed to understand 
the role of these complex receptors in the brain. 
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Figure 31 Model: PPARδ is a protective monounsaturated fatty acid sensor in neurons 
 
A) During HF-SFA feeding, cells are flooded with SFA from plasma, which promote mitochondrial 
ROS production and ER stress leading to activation of inflammatory pathways including NF-κB. 
NF-κB is normally retained in the cytoplasm by IκBα. SFAs promote ER stress and mitochondrial 
ROS production leading to degradation of cytoplasmic IκBα resulting in transcriptional activation 
of proinflammatory NF-κB cytokine target genes that further promote inflammation and insulin and 
leptin resistance. B) MUFAs from HF-MUFA diet activate PPARδ causing transcriptional 
upregulation of UCP2 and mitochondrial uncoupling such that mitochondrial oxidation of FFAs 
does not promote ROS formation. MUFAs do not promote ER stress. Collectively, reduced ER and 
oxidative stress result in low levels of NF-κB activation, thereby maintain insulin and leptin 
sensitivity despite HF diet consumption.  
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ABBREVIATIONS 
 
ACC 
 
acetyl-CoA carboxylase 
ACO 
 
acyl-CoA oxidase 
BAT  brown adipose tissue 
CD36 
 
cluster of differentiation 36 
CNS 
 
central nervous system 
CPT1A 
 
carnitine palmitoyltransferase-IA 
DGAT2 
 
diacylglycerol acyltransferase 2 
DIO 
 
diet-induced obesity 
DBD  DNA binding domain 
EE 
 
energy expenditure 
FAS 
 
fatty acid synthase 
FFA 
 
free fatty acid 
GAPDH 
 
glyceraldehyde 3-phosphate dehydrogenase 
GPAT 
 
gycerol-3-phosphate acyltransferase 
HF 
 
high-fat  
HSC70 
 
heat shock cognate protein 70 
ICV  intracerebroventicular 
IL-1ß 
 
interleukin-1 beta 
IL-6 
 
interleukin-6 
IκBα 
 
inhibitor of NF-κB alpha 
KO 
 
knockout 
LBD  ligand binding domain 
LF 
 
low-fat  
LPL 
 
lipoprotein lipase 
MUFA 
 
monounsaturated fatty acid 
NF-κB 
 
nuclear factor-kappa B 
NPY 
 
neuropeptide Y 
p66shc 
 
p66 Src homology 2 domain containing transforming protein  
PDK4 
 
pyruvate dehydrogenase kinase  4 
PERK 
 
protein kinase RNA-like endoplasmic reticulum kinase 
POMC 
 
Proopiomelanocortin 
PPAR 
 
peroxisome proliferator-activated receptor 
PUFA 
 
polyunsaturated fatty acid 
ROS 
 
reactive oxygen species 
RPL13A 
 
ribosomal protein L13A 
SCD1 
 
stearoyl CoA desaturase 1 
STAT3 
 
signal transducer and activator of transcription 3 
TG 
 
triglyceride 
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TNFα 
 
tumor necrosis factor alpha 
TZD  thiazolidinedione 
UCP2 
 
uncoupling protein 2 
WAT  white adipose tissue 
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